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Abstract

DESIGN AND SYNTHESIS OF MOLECULAR PROBES FOR THE STUDY OF 5-HT2A
AND H1 RECEPTORS

By Jitesh R. Shah, PhD
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Richard B. Westkaemper
Professor, Department of Medicinal Chemistry

The serotonin (5-HT) receptors, with seven subtypes and at least fifteen distinct
members, mediate a wide range of physiological functions both in the central nervous
system and in the periphery.1,2 All members of the 5-HT family except the 5-HT3 subtype
belong to the family of aminergic G protein-coupled receptors (GPCRs).3 Over the years,
various molecules have been reported which act selectively at 5-HT2 receptors.4 However,
there are no ligands that exhibit complete selectivity for one subpopulation of 5-HT2
receptors. Insight into how drugs bind to 5-HT2 receptors could contribute significantly to
the development of subtype-selective agents with enhanced therapeutic effects. We have

xv

begun to address this challenge by the combined approach of chemical synthesis and
molecular modeling. 9-(Aminomethyl)-9,10-dihydroanthracene (AMDA) a novel, selective
5-HT2 antagonist that also has modest affinity for the histamine (H1) receptor has been
reported by Westkaemper et al.5 A structure-affinity relationships (SAFIR) study of
AMDA and its analogs was carried out by studying the effects of N-alkylation, variation of
the amine-ring system linker chain length and constraint of the aromatic rings on the
binding affinities of the compounds for the 5-HT2A and H1 receptors. The results of the
docking studies carried out on the homology models of 5-HT2A and H1 receptors were
consistent with the observed binding affinity data for both receptors. In order to explore the
additional binding site interactions of 5-HT2A receptor, synthesis and testing of the ringannulated analogs of AMDA were carried out. A 3-methoxytetraphen analog of AMDA
(26) showed high affinity (Ki = 21 nM) and selectivity (126-fold) for 5-HT2A receptor as
compared to H1 receptor (Ki = 2640 nM).
Further, to test the utility of our homology models, and investigate the binding site
specific interaction, a compound was synthesized and tested that lacks a basic amine and
contains an acidic functionality designed specifically to interact with lysine K1915.39 found
in H1 but not in 5-HT2A receptor. This compound would thus be both H1-selective and
demonstrate that a basic amine-D3.32 interaction is not necessary for high affinity. The
synthesized compound (34) lacking the nitrogen atom showed moderate affinity at the H1
receptor (Ki = 250 nM), and lacked affinity for 5-HT2A receptors. The modeled ligand
orientations in combination with the observed affinity data provide another example of a
successful structure-based design strategy.
xvi

xvii

INTRODUCTION

1.1 The Discovery of Serotonin
5-Hydroxytryptamine (5-HT), commonly known as serotonin, is one of the
evolutionarily oldest neurotransmitters.7 Its discovery and identification as an important
monoamine neurotransmitter involved a multidisciplinary approach by several groups.8
Serotonin was first described as enteramine, which was isolated from the gut in the 1930s
by Ersparmer and colleagues and revealed to cause contraction of the uterus. In 1948 5-HT
was rediscovered by U. C. Irvine‟s Page group based on its vasoconstrictor properties, its
name being derived from the fact that the substance was produced in the serum (“ser”), and
constricted or increased tone (“tonin”) in blood vessels.9,10 The chemical structure of
serotonin was proposed to be 5-HT by Rapport11 which was then confirmed by Erspamer
and Asero as identical to enteramine obtained from natural sources.10,12,13 Following this
discovery, in 1953 Twarog and Page reported the presence of serotonin in the central
nervous system (CNS),14 which was considered to be one of the major findings in the field
of neuroscience.

1

1.2 Serotonin Biosynthesis and Metabolism
5-HT is synthesized in the human body from the natural amino acid L-tryptophan.
Tryptophan is converted to serotonin via a series of reactions (Figure 1). First, Ltryptophan is hydroxylated to 5-hydroxytryptophan (5-HTP) via the enzyme tryptophan
hydroxylase.15 This reaction constitutes the rate-limiting step in the synthesis of serotonin.
5-HTP is in turn converted to 5-HT via the enzyme amino acid decarboxylase.16 Serotonin
is released into the circulation from the enterochromaffin cells found in the gastrointestinal
(GI) tract and rapidly taken up by platelets via the serotonin transporter (SERT).2 It is then
stored in platelet-dense granules which comprise almost all of the circulating serotonin. In
the central nervous system, serotonin is stored in secretory granules and released from
serotonergic neurons into a synapse. Serotonin is metabolized at the presynaptic terminals
by the monoamine oxidase (MAO) enzyme to 5-hydroxyindole acetic acid (5-HIAA) via
oxidative deamination. Brain 5-HIAA is actively transported to the periphery where, along
with peripheral 5-HIAA, it is excreted in urine.17

1.3 Classification of Serotonin Receptors
In 1957 Gaddum and Picarelli started the subdivision of 5-HT receptors by
studying the effect of 5-HT blockade in guinea pig ileum in the presence of morphine and
dibenzyline. They proposed two receptor classes, 5-HT M and 5-HT D.18 In 1979 Perouka
and Snyder used radioligand binding techniques to describe two classes of serotonin
receptors, 5-HT1 and 5-HT2.19

2
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Figure 1. Biosynthesis and metabolism of serotonin. Cofactors are shown left of the
arrows; enzymes are shown right of arrows.2
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Later Bradley et al.20 proposed the existence three families of 5-HT receptors, named 5HT1-like, 5-HT2 and 5-HT3, the latter corresponding to the M receptor. With the advances
in molecular biology techniques 5-HT receptor genes were cloned, which further led to the
identification of number of new receptors devoid of physiological counterparts.1 Based on
the new findings and a constantly developing field, the serotonin receptor nomenclature
committee proposed a new nomenclature system based on operational, structural and
transductional information.21 To date, 5-HT receptors can be classified into seven families
with at least 15 different subtypes. A majority of these receptors are G protein-coupled
receptors, with the exception of 5-HT3 (5-HT3A and 5-HT3B) which are ligand-gated ionchannel receptors 3,22 (Table 1).

Table 1. Serotonin receptor classification.23

5-HT1

5-HT2

5-HT3

5-HT4

5-HT5

5-HT1A

5-HT2A

5-HT3A

5-HT5A

5-HT1B

5-HT2B

5-HT3B

5-HT5B

5-HT1D

5-HT2C

5-HT6

5-HT7

Coupled
AC (+)

Coupled
AC (+)

5-HT1E
5-HT1F
Coupled
AC (-)

Coupled
PI

Ion
Channel

Coupled
AC (+)

Complex

Second messenger system: Adenylate cyclase (AC), Phosphatidylinositol (PI)
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The 5-HT receptors and a large number of monoamine receptors that belong to the
G protein-coupled receptor (GPCR) family are a part of type A family (rhodopsin-like)
GPCRs.24 The presence of highly conserved residues in rhodopsin, β2-adrenergic receptor
and other type A GPCRs suggests the possibility of serotonin receptors sharing certain
structural and functional similarities with them.25 While the overall homology of GPCRs
compared to rhodopsin is low (35%) in the transmembrane region, the presence of several
highly conserved residues suggests an possible evolutionary relationship.26 The
phylogenetic relationship of each serotonin receptor to others is shown in Figure 2.

Figure 2. Scaled phylogenetic tree comparing all human serotonin receptors with bovine
rhodopsin (BRHO).3
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1.4 Serotonin Receptors: Clinical Significance
Serotonin is a neurotransmitter that plays a role in large number of physiological
processes including regulation of vascular and non-vascular smooth muscle contraction,
platelet aggregation and mitogenesis.27 The greatest concentration of serotonin (90%) is
found in enterochromaffin cells of gastrointestinal tract and the effects of 5-HT are seen
greatly in the cardiovascular system and central nervous system (CNS). Serotonin
receptors contribute to pathological processes related to cardiopulmonary problems,28,29
irritable bowel syndrome,30,31 psychiatric illness (i.e., schizophrenia and mood disorders)3235

Alzheimer‟s disease,36,37 problems involving food and alcohol intake,38,39 and behavioral

problems (i.e. aggression, impulsivity).40,41 Serotonin exerts its effects on neuronal and
non-neuronal tissues by interacting with the various receptor subtype populations (Tables 2
and 3).

Table 2. Mental illness where altered serotonin neurotransmission has been implicated.
(Adapted from Roth, B. L. and Shapiro, D. A., Expert Opin. Ther. Targets, 2001, 5, 685695)42
Disease

5-HT receptor

Prototype drug

Agonist/Antagonist

Schizophrenia

5-HT2A/2C

Clozapine

5-HT2A/2C/6/7 antagonist43

Depression

5-HT1A/1B/2A/2B/2C

Mianserin

5-HT2A/2B/2C antagonist

Anxiety disorders

5-HT1A/1B/2C

Buspirone

5-HT1A partial agonist

Eating disorders/
obesity

5-HT2C

Fenfluramine

5-HT2C agonist44
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Table 3. Common medical conditions in which 5-HT-subtype-selective drugs have utility.
(Adapted from Roth, B. L. and Shapiro, D. A., Expert Opin. Ther. Targets, 2001, 5, 685695)42
Disease

5-HT Receptor

Prototype drug Agonist/Antagonist

Obesity

5-HT2C

Fenfluramine

Agonist45

Irritable bowel syndrome

5-HT3/4/5

Tagaserod

Migraine headaches

5-HT1D/1F

Sumatriptan

5-HT3 antagonist,
5-HT4 agonist
Antagonist

Emesis

5-HT3

Ondansetron

Antagonist

Pain

5-HT2A/2B

Amitryptiline

Antagonist46

Over the years, many studies have been reported with reference to the
pharmacology, molecular biology and the development of selective ligands for these
receptor subtypes.22,47 However, the following discussion will focus on the 5-HT2 receptor
family due to its relevance to the current work. 5-HT2 receptors are one of the most
extensively studied receptor types within the serotonin family. The structure and function
of this group of receptors have been studied in great detail and drugs targeting these
receptors have utility for treating large number of diseases42,48 (Tables 2 and 3).

1.5 5-HT2 Receptor Structure, Function and Localization
The 5-HT2 receptor family members comprise a closely related subgroup of G proteincoupled receptors, functionally linked to a phosphatidylinositol hydrolysis pathway and are
classified as 5-HT2A, 5-HT2B and 5-HT2C subtypes.49,50 While the 5-HT2A and 5-HT2C
receptors are widely expressed throughout the brain, the 5-HT2B receptor is mostly
7

expressed in the periphery, with minimal CNS expression. Each 5-HT2 subtype has a
classic G protein-coupled seven-transmembrane helical region connected by extracellular
and intracellular loops. Most of the current understanding about the structural features of
the 5-HT2 receptor family is derived from mutagenesis and molecular modeling studies of
5-HT2A receptors.3,51,52 The general arrangement of residues in the binding pocket is
similar to that of rhodopsin and large numbers of studies have identified key residues
essential for agonist and antagonist binding to the 5-HT2A receptor.53-56 The binding pocket
of the 5-HT2A receptor is lined with many aromatic residues with the presence of a single
charged residue (D155) which acts as an anchor for aminergic drugs binding to the
receptor.57
The 5-HT2A receptor shares high homology with the 5-HT2C receptor subtype with
overall amino acid sequence identity >50% and the sequence identity between
transmembrane regions >75%.21 The 5-HT2A receptor is highly expressed in all layers of
the cortex with the highest density in the neocortex.50 In the basal ganglia and forebrain, 5HT2A receptor has been localized to medium- and large-sized neurons in the lateral septal
nuclei. The 5-HT2A receptor modulates GABAergic and glutaminergic transmission as well
as monoaminergic transmission via various mechanisms and interactions.49 Given the
extensive location of this receptor in brain areas that mediate cognitive functions and social
interaction, the 5-HT2A receptor is implicated in diseases in which these functions are
impaired. Some of the central disorders involving 5-HT2A receptors are schizophrenia,
depression and psychosis. In addition, recent studies involving 5-HT2A receptor knockout
mice have also implicated its role in sleep disorders.58
8

1.5.1 5-HT2 Receptors in the Development of Novel Antidepressant Drugs
Depression is a common condition that has both emotional and physical
aspects.59,60 It is often accompanied by variety of neurological, psychiatric and other
mental illnesses.59,61 However, no single neurotransmitter abnormality has been identified
that fully explains the pathophysiology of depression. Alterations in the serotonergic and
noradrenergic function in the CNS have often been implicated in the pathophysiology of
depression and the mechanism of action of antidepressant drugs but the specific
impairment that underlies depression is unclear.62,63 The classes of antidepressants drugs
that are commonly used include monoamine oxidase (MAO) inhibitors, tricyclic
antidepressants (TCAs) and the monoamine reuptake inhibitors.64 There have been few
reports suggesting that the depression is caused by the functional deficiency of the
serotonin in the brain.65,66 Studies involving 5-HT2 receptors have indicated that 5-HT2A
antagonism is often associated with significant antidepressant potential67 and that the longterm administration of tricyclic antidepressants causes a decrease in the cortical density of
5-HT2A receptors.68 Thus several clinically-effective antidepressants (mianserin,69
mirtazepine,70 trazadone and nefazadone71) are thought to exert their action by 5-HT2A
antagonism in addition to their action at other receptors.72
In addition, a study involving the functional interaction between central 5-HT and
DA systems has suggested that disinhibition of the mesolimbic DA system might be useful
in the treatment of depression.73 Specifically, the 5-HT2 subtype has been indicated to play
a role in the control of central DA activity because of the moderate to dense localization of
both mRNA and protein for the 5-HT2A and 5-HT2C receptors in the substantia nigra (SN)
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and ventral tegmental area (VTA) in the rat forebrain.74,75 Further, studies have shown that
the 5-HT2C subtype is responsible for the inhibitory influence of 5-HT on the activity of
mesolimbic and nigrostriatal dopaminergic pathways76 (Figure 3) suggesting that 5-HT2
receptors could act as an potential targets for the development of novel antidepressant
drugs.73

Figure 3. Distribution of 5-HT2C and 5-HT2A receptors on GABA-containing and
dopamine-containing neurons in the midbrain. 5-HT2A receptors are expressed on a
subpopulation of DA-containing neurons, and on non-DA neurons whose neurochemical
identity is yet unknown (indicated by question mark). 5-HT2C receptors are expressed on
GABA-containing neurons in both substantia nigra pars reticula (SNr) and the ventral
tegmental area (VTA).73

1.5.2 5-HT2-Selective Antagonists as Potential Antipsychotic Drugs
In the past, studies by Meltzer et al.77 and others have predicted that drugs with
high 5-HT2A/D2 affinity ratios would be effective atypical antipsychotic drugs.78 Since
then, several such atypical antipsychotic drugs (clozapine, olanzapine, risperidone and
ziprasidone) have been approved for clinical use. Generally, atypical antipsychotic drugs
have a complex pharmacology due to their action at multiple serotonin (5-HT2A, 5-HT2B, 510

HT6 and 5-HT7) receptors.79 In addition, atypical antipsychotics also interact with
dopamine D4 and muscarinic (M1-M5) receptors. It is assumed that 5-HT2A rather than 5HT2C receptors play a major role in mediating psychosis, which suggests that the variable
degree of 5-HT2A vs. 5-HT2C receptor selectivity between atypical antipsychotics may be of
clinical relevance. In fact, antagonism of 5-HT2A as well as 5-HT2C receptors has been
implicated in the therapeutic effectiveness of atypical antipsychotics.80 The role of 5-HT2A
receptors in psychosis is supported by the report of MDL100907,81 amperozide,
eplivanserin and ritanserin as compounds preferring the 5-HT2A receptor; however,
development has been limited.82 Due to the multiple receptor affinity of the atypical
antipsychotics they are often associated with side effects. Thus the development of
selective 5-HT2A antagonists might provide an effective therapy for psychosis in addition
to acting as pharmacological tools for the study of the 5-HT2A function.

1.5.3 5-HT2 Ligands in the Treatment of Schizophrenia
Schizophrenia is one of the major neuropsychiatric disorders that involve the 5-HT
and DA neurotransmitters.83 It is diagnosed by its positive symptoms (auditory
hallucinations, disorganized thoughts and delusions), negative symptoms (social
withdrawal, lack of motivation) and cognitive dysfunction.84 The first-generation
antipsychotics and the newer atypical antipsychotic drugs are the main line of treatment for
schizophrenia.85,86 However, the negative symptoms and cognitive dysfunction are not
fully treated by them.87 Recent studies have shown that the 5-HT2A receptor subtype plays
an important role in schizophrenia by modulating dopamine release in the striatum and
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cortex.33,88 In addition, the antiserotonergic properties of atypical antipsychotics decrease
the dopamine activity in the frontal cortex that in turn may contribute to improvement in
negative symptoms in schizophrenia.89 Recent studies have also linked the association of
the T102C polymorphism in the 5-HT2A receptor gene with schizophrenia.88,90,91 The 5HT2A receptor is considered to be a major component of the atypical antipsychotic profile,
and atypical antipsychotic drugs used in therapy are known to bind to 5-HT2A
receptors.92,93 However, the use of atypical antipsychotic drugs is often associated with
adverse side effects such as metabolic disorders, sedation, movement disorders and weight
gain.84 One of the possible reasons for the side effects of these drugs is their multiplereceptor (serotonin, dopamine, α-adrenergic, muscarinic and histamine) binding profile.94
Thus the development of newer atypical antipsychotic drugs having selectivity for the 5HT2A receptor can potentially lead to clinically useful drugs for the treatment of
schizophrenia.

1.5.4 5-HT2 Ligands in the Treatment of Sleep Disorders
It is well established that serotonin plays major role in the regulation of sleepwakefulness cycles (Figure 4), and that any disruption of serotonergic function induces
modification of sleep and waking.95 Evidence from clinical studies has suggested that 5HT2 receptors modulate slow wave sleep (SWS).96 For example, the 5-HT2 receptor
antagonist ritanserin promotes sleep and enhances slow wave activity in humans and rats. 91
This activity is likely mediated through the 5-HT2A receptor, as similar increases in SWS
are observed with more selective 5-HT2A antagonists such as eplivanserin97 and
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MDL100907.98 In addition, studies involving knock-out mice lacking 5-HT2A receptors
have suggested that the 5-HT2A subtype is involved in non-rapid eye movement sleep
(NREMS) regulation58 and that the ligands acting at 5-HT2A receptors might be useful in
the treatment of sleep disorders. Thus by improving the quality of sleep and restfulness, 5HT2A modulators (antagonists/inverse agonists) can offer a significant advancement in the
treatment of sleep disorders.
Nucleus Raphe Dorsalis

Hypothalamus
Synthesis of
sleep -promoting
substances

5-HT

via 5-HT1A
and 5-HT2
receptors

active

During Wakefulness
Cholinergic
"PS-on" neuron
inhibited
Via 5-HT1A
receptors

inactive

During Paradoxial sleep

active

Figure 4. Schematic representation of the serotonergic regulation of sleep-wakefulness
cycle. During waking, the serotonergic neurons of nucleus raphe dorsalis (NRD) are active.
5-HT is liberated at the termini and activates postsynaptic serotonin receptors. This
activation results in an increase sleep-like condition at the hypothalamic level and
inhibition of cholinergic structures responsible for paradoxical sleep (PS) at the pontine
level. During sleep, the serotonergic neurons are inactive, possibly due to a negative
feedback loop via a sleep-promoting substance. This result in a reduction in both 5-HT2
influence (facilitating occurrence of SWS) and 5-HT1A inhibitory control of cholinergic
“PS-on” neurons, therefore facilitating the occurrence of PS.99
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1.6 Clinical Relevance for Studying Serotonin (5-HT2A) and Histamine (H1) Receptors
Histamine is another monoamine which is known to regulate a wide variety of
physiological responses.100 It acts as one of the primary inflammatory mediators released
from mast cells following allergic challenges.101,102 It also acts as a neurotransmitter in the
central nervous system (CNS).103 Histamine exerts its effect by interacting with four
different aminergic GPCRs H1-H4104 (Table 4).
Table 4. Histamine receptor classification. (Adapted from Fung-Leung, et al., Curr. Opin.
Invest. Drugs, 2004, 5, 1174-1183).105
Histamine
receptor
Expression

Gα-protein
association
Signaling
Key
function
Agonists
Antagonists

H1

H2

H3

H4

Ubiquitous

Ubiquitous

Neural cells

Gαq

Gαs

Gαi/o

Mast cells,
eosinophils,
dendritic
cells and Tcells
Gαi/o

↑Ca+2
Bronchoconstriction
and vasodilation

↑cAMP
Gastric acid
secretion

↓cAMP
Neurotransmitter
release

2-Methylhistamine,
Histaprodifen

Dimaprit,
Anthamine

R-αmethylhistamine,

↑Ca+2
Mast cell and
eosinophil
chemotaxis
Imetit,
Immepip

Imetit
Thioperamide
Clobenpropit

JNJ-7777120

Diphenhydramine
Cetrizine
Pyrilamine

Burimamide
Cimetidine
Ranitidine

Thioperamide

Over the years various classes of H1 antagonist have been developed and used
clinically106,107 (Figure 5). However, because of CNS penetration and central H1 receptor
blockade their clinical use is hampered by various side effects, most notably sedation.108,109
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Figure 5. Structures of representative H1 antagonists.
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This led to the development of second-generation antagonists (acrivastine,
loratadine, terfenadine, cetirizine, etc.) that exhibited less sedative potential due to the
decrease in their ability to penetrate the blood-brain barrier.107,110,111 Some of these
antagonists, such as doxepin, ketotifen, and epinastine that have a tri- or tetracyclic fused
ring system also showed affinity at 5-HT2A, adrenaline α1, dopamine D2 and muscarinic M1
receptors, indicative of their low selectivity for the H1 receptor.112-114 Among the various
chemical classes of H1 antagonist, ligands that are zwitterionic (olopatadine, acrivastine,
fexofenadine) showed an improved degree of selectivity for H1,115-117 suggesting a specific
interaction of the carboxylate group on the ligand with the H1 receptor. Introduction of a
carboxylate moiety thus provides one potential means of designing H1-selective
antagonists with reduced sedative potential.
There have been three reports suggesting that serotonin may be the primary
neurotransmitter in the control of sleep states.95,118,119 However to date, drugs which
modulate serotoninergic transmission by stimulating or blocking serotonin receptors have
not been used clinically in the treatment of insomnia.120 Studies related to 5-HT2
antagonists including the antipsychotics ziprasidone and risperidone have shown that these
drugs increased slow wave sleep (SWS) and affect NREM.96,121 Nevertheless, the study of
the clinical role of 5-HT2A receptors in sleep has been hampered by the lack of 5-HT2A
selective agents. Thus there is a need for a selective agent for the determination of the role
of 5-HT2 receptors in sleep as a lead to the possible development of a sleep drug based on
5-HT2A antagonism.
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In addition to serotonin, histamine has been proposed to be involved in the control
of sleep and wakefulness, as mentioned previously.122 Most common over-the-counter
agents used to promote sleep are antihistamines. Development of improved antihistaminic
drugs for the treatment of insomnia is hampered by the fact that these drugs have action at
multiple targets including serotonergic and muscarinic receptors. There has been a recent
report of the use of low-dose of doxepin (an antidepressant agent with high affinity and
selectivity for H1 receptor) in the treatment of insomnia, suggesting a potential role for
selective H1 receptor antagonists in the treatment of sleep disorders.113 In addition, the
latest reports of clinical trial studies123 have also implicated the role of selective dualacting 5-HT2A/H1 ligands in the treatment of sleep disorders. As mentioned earlier, the
majority of atypical antipsychotic drugs (clozapine, risperidone, olanzapine, ziprasidone,
aripiprazole) used in the treatment of schizophrenia exhibit high affinity for the 5-HT2A
receptor. However, they are often associated with the side effects such as weight gain.
Results from a recent study have suggested that the histamine H1 receptor is the most likely
molecular target responsible for atypical antipsychotic drug-induced weight gain.124 Thus,
the study of factors relating to the selectivity between H1 and 5-HT2A receptors could also
help in the design of next-generation atypical antipsychotic drugs with fewer side effects.

1.7 5-HT2 Receptor Ligands
The 5-HT2 family of serotonin receptors represents major target for drugs used in
the treatment of a variety of diseases as mentioned earlier. As the 5-HT2 family of
receptors has three members (5-HT2A, 5-HT2B and 5-HT2C), the development of subtype17

selective compounds will be needed in order to avoid side effects and to enhance
therapeutic value. Unfortunately not many ligands are available which exhibit subtype
selectivity.125 Some of the ligands that act at 5-HT2 receptors are shown in Figure 6. The
indolealkylamine ligands act as 5-HT2A agonists but are less selective as compared to
phenylalkylamines such as DOB and DOI that exhibit low affinity at non-5-HT2 sites.
However, phenylalkylamines also cannot differentiate among 5-HT2 subpopulations.126
One of the most selective antagonist classes of 5-HT2A ligands are the N-alkylpiperidines,4
(e.g. ketanserin); although ketanserin only shows about 10- to 15- fold selectivity for 5HT2A versus 5-HT2C receptors. Various analogs of ketanserin have been made, but not
much selectivity has been achieved. The other 5-HT2A antagonists such as ritanserin, MDL
100907,81 spiperone,127 risperidone and olanzapine demonstrate increased selectivity for 5HT2A.82,120 Various nonspecific tricyclic agents (tricyclic neuroleptics and antidepressants)
bind at 5-HT2A receptors.128 A range of new compounds reported to have activity at 5-HT2A
receptors is under clinical development.129
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1.8 Understanding 5-HT2A Receptor-Ligand Interactions and Development of a
Selective GPCR Ligand
The 5-HT2 family of receptors has three members (5-HT2A, 5-HT2B and 5-HT2C)
and development of 5-HT2-selective compounds is expected to lead to drugs with better
therapeutic indices. To date, very few truly selective 5-HT2 receptor ligands have been
discovered and found to have clinical application. One of the challenges in the
development of a subtype-selective ligand is the possible interaction with the multiple
serotonin receptor subpopulations (5-HT1 through 5-HT7) and the serotonin transporter
(SERT). In an attempt to develop a selective 5-HT2 ligand and understand how the
molecules bind at these receptors, we decided to use receptor structure-based drug design.
Integrating data from molecular models, site-directed mutagenesis studies and traditional
SAR studies makes it possible to generate new and interesting leads. With the introduction
of a structure of a true aminergic (β2-adrenergic) GPCR130,131 in addition to existing bovine
rhodopsin structures, homology modeling techniques are better-equipped to produce
biologically relevant GPCR models.
In an effort to develop a 5-HT2-selective ligand, we started with a simple
nonselective structural template (phenylethylamine) having low affinity for the 5-HT2A
receptor (Ki = 16,800 nM) and modified its structure so as to enhance affinity and
selectivity. Initial investigations5,51 in our laboratory have led to the development of
AMDA (9-aminoalkyl-9,10-dihydroanthracene; Ki = 20 nM), a novel 5-HT2 antagonist
having moderate affinity at histamine H1 (Ki = 197 nM) receptors. Using structure-based

20

drug design methods and AMDA as a lead compound, testable hypotheses were generated
and compounds were designed to test these hypotheses.

1.9 Specific Aims of the Research Project
Taking into account the lack of the experimentally derived 5-HT2 receptor structure
and the need to understand the 5-HT2A receptor-ligand interactions, a set of specific aims
were devised as follows:
Aim 1) To design and synthesize ligands based on AMDA (9-aminoalkyl-9,10dihydroanthracene) and its pharmacophore as molecular probes for the study of the 5-HT2A
and H1 receptor binding sites.
Aim 2) To test hypotheses relevant to the affinity/selectivity of the compounds at the 5HT2A and the H1 receptor using ligand SAR, homology modeling and existing site-directed
mutagenesis studies.
Aim 3) To use the information acquired in the above investigations for the refinement of
homology models and test the utility of our models for the design of new H1- and/or 5-HT2
-selective compounds.
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MOLECULAR MODELING OF G PROTEIN-COUPLED
RECEPTORS

2.1 Introduction
G protein-coupled receptors (GPCRs) are vital components of biological signaling
processes in higher animals and humans, which constitute one of the most important set
of targets for pharmaceutical industry.132 More than 1000 genes encoding GPCRs have
been identified from the human genome sequencing effort. This represents a substantial
part of human genome (~3%). On the basis of structural and sequence similarities,
GPCRs are generally classified into 5 families: Class A (rhodopsin-like) is the largest
group and contains receptors for classical neurotransmitters (biogenic amines and
nucleotides) and a large variety of peptides and lipids, with class B (secretin), class C
(glutamate), class D (fungal hormone), class E (cAMP)133,134 and class F (frizzled)
comprising the remaining classes. The physiological function of a large fraction of these
GPCRs is unknown; these receptors are referred to as orphan GPCRs.135
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2.2 Central Role of G Proteins
On activation, GPCR‟s trigger a cascade of intracellular responses through
interactions with their associated heterotrimeric G proteins.136 The G proteins are a
family of closely related membrane-linked polypeptides. By acting as a carrier they form
central elements for the signal transduction between the receptors and the effector
components (enzymes or ion channels) in the cytoplasm. At rest, they consist of a
heterotrimer possessing a guanine nucleotide-binding α subunit (40 - 52 kDa), a β subunit
(35 kDa) and a γ subunit (98 - 100 kDa). The β-γ complexes are presumed to be
exchangeable from one G protein to another.137 G proteins are peripheral membrane
proteins, in contrast to integral membrane proteins which span the entire membrane (e.g.
GPCRs). Activation of the receptor promotes the exchange of a molecule of GDP with a
molecule of GTP within the active site of the α-subunit. The binding of GTP causes the
dissociation of the heterotrimeric complex, and both the GTP-bound α subunit and the
released β-γ complex are then able to interact with intracellular or membrane effectors.
The intrinsic GTPase activity of the α-subunit hydrolyses GTP to GDP, restoring its
initial inactive conformation as well as its affinity for the β-γ complex (Figure 7).

2.3 Common Structural Features of GPCRs
GPCRs share a common structural motif of seven hydrophobic transmembrane
(TM) segments, three extracellular loops (EL), an extracellular amino terminus, three
cytoplasmic loops and an intracellular carboxyl terminus. They share the greatest
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homology within the TM segments. Each of the TM regions is composed of
approximately 20-30 amino acids.

Inactive G protein

γ

β

αs
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GDP

GTP
Active G protein
Stimulated effectors Component
Figure 7. Role of G Proteins.137

The most variable structures among the family of GPCRs are the carboxyl
terminus (12 - 360 amino acids) the third intracellular loop (5 - 230 amino acids) and the
amino terminus (7 - 595 amino acids). Amongst these the greatest diversity is observed in
the amino terminus. This sequence is relatively short (10 - 50 amino acids) for the
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monoamine and peptide receptors, and much larger (350 - 600 amino acids) for
glycoprotein hormone receptors and the glutamate family receptors.137
The 7TM structure of GPCRs has certain structural and functional merits as noted
by Ji et. al.138 The odd number of TMs places the N- and C-terminal segments at opposite
membrane surfaces that allows glycosylation and ligand binding at the N-terminal
segment (for non-aminergic GPCR‟s), and phosphorylation and palmitoylation at the Cterminal segment for desensitization and internalization. Also, seven TMs may be the
minimum necessary to form six loops and a TM core with a sufficient size and versatility
to offer an unusual number of specificities, regulatory mechanisms, and contact sites for
G protein and other signal molecules. TM α-helices vary in sequence length and can
extend beyond the lipid bilayer.139 Therefore, the boundaries between TMs and loops are
likely to be uneven and may be dynamic. TMs 1, 4, and 7 are significantly more
hydrophobic than TMs 2, 3, 5, and 6 that contain several ionic and/or neutral residues that
are hydrophilic. Proline residues frequently found in TM α-helices kink the helix
backbone by ~26° and impact the global structure. The seven TMs are arranged as a
closed loop in the counterclockwise direction from TM 1 to TM 7 when viewed from the
extracellular surface (Figure 8A). The orientation of the TMs imposes a steric and
geometric specificity on a ligand‟s entry into and binding to the TM core.140 In this
arrangement, the core is primarily comprised of TMs 2, 3, 5, 6, and perhaps 7, whereas
TMs 1 and 4 are peripherally sequestered. This arrangement is consistent with the view
that the more hydrophobic TMs 1, 4, and 7 are exposed more to the lipid bilayer than the
less hydrophobic TMs 2, 3, 5, and 6. The high resolution 3D structure of
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bacteriorhodopsin141,142 suggest that the TM core is tightly packed by hydrogen bonds
and salt bridges between the residues of same TMs as well as other TMs. Disulfides
linkages often play a major role in the structure and stability of proteins. Among
numerous cysteine residues found in eukaryotic GPCRs, two conserved cysteine residues
in EL2 are known to be linked by a disulfide bond in bovine rhodopsin and other GPCRs.
This disulfide constrains the EL2 loop, preventing it from moving too far away from the
TM helical bundle.143,144
In contrast to the structural and functional similarity of GPCRs, the types of
natural GPCR ligands interacting with them are structurally wide-ranging. The diverse set
of ligands is comprised of small organic molecules, subatomic particles (e.g. photons),
ions, peptides and proteins. The location of ligand binding domains for a few GPCRs has
been determined and has been postulated for many others. While many small molecule
agonists bind within the TM segments, peptide hormones and proteins often bind to the
amino terminus and extracellular loop regions 138,145 (Figure 8B-F).

2.4 Challenges in GPCR Research
In spite of remarkable advances in the biology and pharmacology of GPCRs,
progress in the area of protein structure has been more limited. Until the recent reports of
the crystal structure of human β2-adrenergic receptor130,146 the only high resolution
structure of a GPCR was that of the bovine rhodopsin.142
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Figure 8. GPCRs structure and receptor-ligand interactions.138
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2.4.1 Why are there only a few Experimental Structures of GPCRs?
Some of the major obstacles to obtaining structures of GPCRs include protein
expression, purification, and protein stability.147 Crystallization of membrane protein is
often a very difficult and time consuming process. With the exception of rhodopsin,
which is present in abundant amounts in rod outer segments, membrane proteins occur at
relatively low concentration in cell membranes. Another problem associated with
crystallization of these receptors is their conformational flexibility. To orchestrate the
complex signaling pathways the helical bundle of GPCRs adopt various conformations
(active and inactive states) leading to conformational heterogeneity. In addition, the polar
surface area available for crystal contacts is limited because of the receptor residues that
are predominantly nonpolar being buried in the membrane bilayer. Purified GPCRs are
not stable in detergent compatible with crystallography.148 They tend to be more stable in
non-ionic detergents with relatively long alkyl chains. These detergents may form large
micelles that prevent the formation of crystal contacts.149 The successful addressing of
these problems, with the recent advances in crystallographic techniques is accelerating
the progress in this area of research. Meanwhile, to keep up with the rate of newly
discovered GPCR sequences, one may rely on alternate solutions such as generation of
3D models based on the available crystal structure data of a few GPCRs.

2.5 Homology (Comparative) Modeling as a Workable Solution
Given the scarcity of crystal structures for GPCRs, the study of this family of
proteins has been greatly advanced through the use of structural models.150 These models,
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combined with experimental testing, have proven to be successful tools to obtain a
structural understanding of the GPCR function, and the characteristics of the ligand
binding sites.151 Homology modeling is a method for constructing a three dimensional
model of a protein sequence based on the structure of homologous proteins. Steps
involved in building a homology model are 1) Identifying the homologous protein(s) and
determining their sequence similarity with the unknown; 2) Alignment of the receptor
sequence to be modeled with those of the template(s); 3) Identification and mutation of
residues in the structurally conserved regions; 4) Generation of conformations for the
structurally variable regions (primarily extracellular and intracellular loops); 5) Building
and optimization of the side-chain conformation; 6) Evaluation and refinement of the
generated model.

2.5.1 Bovine Rhodopsin and β2-Adrenergic Receptor Structures as Suitable
Templates for Homology Modeling
The general observation that evolutionarily related proteins share a similar 3D
structure inspite of the fact that they have different amino acid sequences has led to
protein models from structurally different templates. By far the most common way the
inactive state of a GPCR is modeled is based on the crystal structure of bovine
rhodopsin.142,152 All rhodopsin-like GPCRs are likely to share a common topography with
7TMs bundled together in a similar manner. Sequence comparison has revealed specific
amino acid patterns characteristic of each TM that are highly conserved in class A
GPCRs. These conserved amino acid residues are also the basis of a commonly used

29

GPCR residue indexing system introduced by Ballesteroes and Weinstein.153 (Briefly, the
most conserved residue in a given TM is assigned the index X.50, where X is the TM
number. The remaining residues are numbered relative to position 50). These specific
conserved residues are 1) N1.50, D2.50, N7.50. They contribute to the stabilization of 3D
structures of TM1, TM2, and TM7 and their mutation produces serious effects in function
of the receptor.154 2) The D/ERY motif in TM3 and E6.30 in TM6. The central arginine
(R3.50) of the D/ERY motif makes a hydrogen bond with the adjacent D3.49 and a
highly conserved glutamic acid in TM6 (E6.30). For a number of GPCRs, mutations in
this motif induce a constitutively active phenotype, and thus it is assumed that this motif
holds the receptor constrained in the ground state.52,155 3) The aromatic cluster including
highly conserved F6.44, W6.48, F6.51, and F6.52. UV absorbance studies and site
directed mutagenesis have shown a conformational change of W6.48 upon rhodopsin
activation, consistent with a change in the relative orientation of helices of TM3 and
TM6.156 Computational studies have shown that the conformation of W6.48 and F6.52
are highly correlated, and may constitute a rotamer “toggle switch” that may modulate
the TM6 proline kink. W6.48 and P6.50 are likely to share a common functional role
enabling the activation of receptor.157 4) The NPXXY motif in TM7. The crystal structure
of rhodopsin reveals that this motif induces a large distortion in TM7 which is stabilized
by hydrogen bond between polar N7.49 and a network of waters that connect it with
D2.50. Studies have demonstrated that NPXXY motif and helix 8 play an important role
in the activation process, binding of the G-proteins and may act as a conformational
switch domain involved in activation.158
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Recently a crystal structure of the β2-adrenergic receptor (3.4 Å) was reported as a
receptor-antibody complex with carazolol (inverse agonist) bound in the helical region. 130
Although the β2AR structure represents the truncated versions, the overall topology of
rhodopsin and β2AR are quite similar. The root mean square deviation (RMSD), which is
measure of structural similarity between protein‟s structures for alpha carbon backbone
of TM region between the two is 1.56 Å which indicates similar arrangement of TM
helices. Also, a high resolution (2.4 Å) crystal structure of engineered β2-adrenergic
receptor-lysozyme T4 fusion protein has been reported that is similar to the antibody- β2AR complex.131,146 Among the major differences which exist between rhodopsin and β2AR relevant to the ligand binding site are the disposition of the helical segments and the
second extracellular loop (Figure 9). In case of β2AR the EL2 loop contains a short helix.
This helix contains two disulfide bonds which appear to maintain the loop in a
constrained state presumably providing space for diffusion of ligands into the binding site
of the receptor, whereas in rhodopsin the second extracellular loop contains a buried βhairpin which forms a cap-like structure that isolates the retinal-binding site in a
hydrophobic pocket. Another difference between two structures is in the state of “ionic
lock” defined as the network of hydrogen bonding and charge interactions between R131
in TM3 and E268 in TM6 for β2AR and R135 and E247 in rhodopsin. The ionic lock is
proposed to maintain rhodopsin and other class A GPCRs in an inactive conformation.
Disruption of this interaction is thought to allow formation of the active conformation.
The crystal structure of inactive rhodopsin displays an ionic lock with a distance of 2.9 Å
between E247 and R135. However in both β2AR structures the ionic lock is broken with
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a R131-E268 distance of >6.0 Å. Evaluation of the ligand binding site, carazolol (in
β2AR) and cis-retinal (in rhodopsin) reveals difference in their interaction with the highly
conserved “rotamer toggle” (W265 in rhodopsin and W268 in β2AR). It has been
proposed that a change in the rotameric state of this tryptophan in class A GPCRs serves
as a second activation switch. Although carazolol does not directly interact with W286 in
β2AR it appears to control the rotameric state of W286 indirectly via interaction with
F289 and F290.
In the absence of an experimentally-determined structure for either 5-HT2A or H1
receptors, rhodopsin and β2-adrenergic receptor crystal structures were used to create
homology models of these receptors. Each template has certain advantages and
disadvantages which justifies its selection. For example it is not clear if the β2AR/T4
lysozyme fusion protein is in the inactive or active state while the rhodopsin structure has
been extensively studied (biophysical characterization) and crystal structures for both
active and inactive states have been determined. On the other hand, β2AR is an aminergic
GPCR that reversibly binds ligands whereas the rhodopsin ligand, retinal, is covalently
linked to the receptor. Moreover the sequence homology is higher between 5-HT2A /H1
and β2AR than between 5-HT2A/H1 and rhodopsin. The overall goal of this project was to
determine ligand-receptor interactions for the serotonin 5-HT2A receptor for selected
target compounds. 5-HT2A is a typical rhodopsin-like aminergic GPCRs consisting of two
soluble domains (extracellular N-terminal, intracellular C-terminal) and seven
hydrophobic regions corresponding to seven transmembrane-spanning (7TM) helices. In
order to determine the receptor-structure based affinity and selectivity of ligands for the
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5-HT2A and H1 receptors, homology models of the 5-HT2A and H1 receptors were built
using both bovine rhodopsin and the recently reported structure of the human β2adrenergic receptor as templates.

b

a

c

Figure 9. a) Superimposition of the 5-HT2A GPCR models based on β2-AR (orange: PDB
2RH1) and rhodopsin (green: PDB 1U19) crystal structures. b) Conserved residues in
rhodopsin based model and c) β2-AR based model.
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2.6 Construction of Homology Models
Models of the 5-HT2A and H1 receptors were built using two primary homology
modeling techniques.
1) Manual approach. An alignment of the primary amino acid sequences was
carried out using the ClustalX program.159 The adjustments to the alignments were made
wherever necessary. In the structurally conserved regions (primarily TMs) there was a
high degree of sequence similarity and no insertions or deletions. Hence the amino acids
were directly mutated from bovine rhodopsin to the corresponding residues in the
template receptor (5-HT2A and H1). Most of the loop regions connecting the TM helices
were of varied length and low in sequence homology, so they were modeled using a loop
search facility (selection of loops from a database of high resolution protein structures
found in the PDB) in the SYBYL molecular modeling package.
The N-terminal region of the 5-HT2A receptor is of different length and showed
little sequence similarity to the templates. Deletion of N-terminus from the 5-HT2A
receptor does not appear to affect receptor function160 so explicit consideration of the Nterminal segment was not given for the generation of 5-HT2A and H1 models. The
rhodopsin crystal structure consisted of only the first 18 residues in the C-terminus. A
short α-helical segment (Helix 8) is present at the beginning of C-terminus following
TM7. Helix 8 is perpendicular to the TM helix aggregate and is preceeded by the
NPXXY motif of TM7 that is common to 5-HT receptor sequences. The side chains were
then placed in the final model and checked for stereochemical integrity using the
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PROCHECK161 and ProTable feature within the SYBYL. The final receptor model was
then energy-minimized.
2) MODELLER-generated models. Based on ligand binding studies and
generation of constitutively active receptors, it has been implied that the rhodopsin can
exist in two receptor states. Thus a ligand can bind to and stabilize the receptor, which
can exist in various different conformations. In order to consider this conformational
flexibility of the receptor, MODELLER162 program was used in the generation of a
population of receptor models, each with a slightly different conformation. MODELLER
builds models of 3D structures of proteins by satisfaction of the spatial restraints. These
restraints include the positions of the atoms in the template structures, distances and
dihedral angles in the template structures. Stereochemical restraints such as bond length
and bond angle are obtained from the CHARMM forcefield, and statistical preferences of
dihedral angles and non-bonded atomic distances were obtained from a representative set
of protein structures.
The 5-HT2A (P28233) receptor sequence was aligned with a profile of several
related class A GPCRs using the ClustalX program. Manual adjustment of the ClustalX
alignment was required to properly align the disulfide-forming cysteine residues in the e2
loop. The result was an unambiguous alignment in the transmembrane (TM) helical
regions of both the H1 and 5-HT2A sequences with that of the bovine rhodopsin. This
alignment, along with a file containing the atomic coordinates of the inactive form of
rhodopsin receptor (PDB ID = 1U19) or β2-AR receptor (PDB ID = 2RH1), was used as
input to the MODELLER software package to generate a population of 100 different
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5-HT2A homology models. Each of these receptor models was subsequently energyminimized. The selection of the best fit model was done based on the observed
interactions of the docked pose of the set of high affinity ligands (see experimental
section), the reported site directed mutagenesis data for the respective receptors (H1 and
5-HT2A) and the observed GOLD scores. In addition to using the GOLD score, HINT
(Hydropathy Interaction)163 score was also used to characterize the nature of the binding
site. An attempt was made to correlate the experimentally obtained binding affinity data
with the GOLD scores and the HINT scores; however a very modest correlation was
obtained.

2.6.1 Docking and Scoring methods for ligands
Following the generation of final models, the automated docking program
GOLD164 (Genetic Optimization for Ligand Docking) was then used to optimally place
the ligands in the binding site of receptor models. The GOLD program uses a genetic
algorithm to sample the complete range of ligand conformational flexibility with partial
flexibility of the protein, and satisfies the basic requirement that the ligand must displace
loosely bound water on binding. It works as follows: A population of potential solutions
(i.e. possible docked orientations and conformations of the ligand) is set up at random.
Each member of the population is encoded as a chromosome, which contains information
about the mapping of protein ligand interactions. Each chromosome is assigned a fitness
score based on its scoring function and the chromosomes within the population are
ranked according to fitness. The population of chromosomes is iteratively optimized. At
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each step, a point mutation may occur in a chromosome, or two chromosomes may mate
to give two children chromosomes. The selection of chromosomes is inclined towards
fitter members of the population, i.e. chromosomes corresponding to ligand dockings
with good fitness scores. The fittest chromosomes are then used as the starting point of
the next iteration. The GOLD program provides three different scoring functions 1) Gold
Score. The original scoring function provided with GOLD, which has been optimized for
the prediction of ligand binding positions and takes into account factors such as Hbonding energy (intra/inter molecular), van der Waals energy and ligand torsion strain. 2)
ChemScore. It estimates the total free energy change that occurs on ligand binding and is
trained by regression against binding affinity data. As the fitness scores are
dimensionless, they cannot be used explicitly as values for binding energy or binding
affinity 3) ASP (Astex Statistical Potential)165 is an atom-atom potential derived from a
database of protein-ligand complexes. Assessment of the docking and scoring methods
indicated that reasonable results were obtained with ChemScore function of GOLD. This
docking/scoring combination was used in most of the studies.
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STRUCTURE-AFFINITY RELATIONSHIP STUDIES OF
AMDA AND ITS ANALOGS AT 5-HT2A AND H1 RECEPTORS

3.1 Introduction
The serotonin 5-HT2 and histamine H1 receptors have been implicated in various
central nervous system (CNS) related disorders.42,109,166 In the absence of an
experimentally-determined structure of a 5-HT family receptor, most structure-based
drug design and optimization have relied on the information gained by structure-activity
relationship (SAR) studies. Many SAR studies

51,125,167

for the 5-HT2 ligands and their

potential therapeutic uses 82,120,168 have been reported which stress the importance for the
development of subtype selective ligands. In addition, the recent reports of the role of 5HT2A receptors in non-rapid eye movement sleep (NREMS) regulation and respiratory
control,58 suggest that selective antagonism of the 5-HT2A receptor may be a promising
new mechanism for the treatment of sleep disorders.169
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Thus, study of the 5-HT2

receptor‟s binding site and generation of 5-HT2 subtype-selective agents have been of
considerable interest.
Molecular modeling studies based on the 5-HT2A receptor sequence and highresolution crystal structure of bovine rhodopsin have been reported by Westkaemper et
al. and others to envision ways in which the existing and new compounds may interact
with the residues in the ligand binding site.170,171 Some of these studies suggested that the
affinity of structures containing a phenylethylamine skeleton for the 5-HT2A receptor
could be enhanced by a second aromatic moiety, perhaps by participating in the
additional aromatic-aromatic interactions between the ligand and the receptor.172 This
ultimately led to the design of 9-(aminomethyl)-9,10-dihydroanthracene (AMDA), which
has proven to be a unique 5-HT2 antagonist.5 Although AMDA was structurally unique
and simple, it became apparent that the AMDA structure bears general similarity to two
classes of known drugs- tricyclic antidepressants and antipsychotic agents. Both of these
classes are tricyclic amines consisting of two aromatic groups and a central non-aromatic
ring that bears an alkylamine linker chain as in AMDA. Also, most clinically useful
tricyclic amines are conformationally flexible. Since alkylamine chain length and Nalkylation

are

two

major

structural

features

that

distinguish

AMDA

from

conformationally flexible classical tricyclic amines, our group investigated the influence
of chain length and N-alkylation in a series of AMDA analogs and compared to
imipramine.173,174 Also, a series of AMDA analogues were tested to determine the
importance of the tricyclic ring system, and the effect of restricting the conformational
freedom of the ammonium ion on 5-HT2A receptor affinity. This resulted in the synthesis
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of spiro[9,10-dihydroanthracene]-9,3‟-pyrrolidine (SpAMDA), a conformationally
constrained analog of AMDA.175 Both AMDA and SpAMDA proved to be high-affinity
antagonists for 5-HT2A/2C receptors with better selectivity for these receptors as compared
to the D2 receptor and serotonin and norepinephrine transporters, unlike the tricyclic
antidepressants.
Histamine released by tissue mast cells, basophils and histaminergic neurons is
also known to impact the ability to fall asleep and stay asleep.176 Research and
development of H1 ligands have focused largely on antagonists that are used for their
antiallergic effects in the periphery. However, the first-generation H1 receptor antagonists
(e.g. diphenhydramine, mepyramine, chlorpheniramine) also exhibit high H1 receptor
occupancy in the CNS due in part to their lipophilicity, leading to sedative effects. 177,178
Recent reports of the clinical trial studies have indicated that compound acting at both 5HT2A and H1 receptor enhances sleep and should have low abuse potential.123 Thus the
study of ligands acting at both 5-HT2A and H1 receptors could be therapeutically relevant.
Binding studies conducted for the selectivity profile of AMDA and its analogues showed
that SpAMDA had high affinity for H1 receptors (Ki = 4 nM), while AMDA showed
moderate affinity (Ki = 197 nM). Given the potential therapeutic use of dual 5-HT2A/H1
ligands in the treatment of sleep disorders we decided to continue our studies on the
AMDA structure and carried out the systematic structure-affinity relationship (SAFIR)
studies of AMDA and its analogs.
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3.2 Results and Discussion
3.2.1 Structure-Affinity Relationship Studies
Several

reviews

describing

structure-activity

relationship

studies

of

diphenhydramine-like antihistamines have been reported.178-180 The features that have
been systematically varied include the nature of the two required aromatic groups, the
terminal basic amine and the aliphatic linker between these two features. We have
examined similar structural variations with AMDA as the parent structure. Note that
replacement of the ether oxygen of diphenhydramine by a methylene unit results in
compound 18 (Table 5). Replacement of the pyridin-2-yl group of the H1 antagonist
pheniramine with phenyl results in 15. Binding affinities of the compounds for the 5HT2A and H1 receptors are shown in Table 5 and displayed graphically in Figure 10. The
most significant differences in affinity for both 5-HT2A and H1 receptors were observed
between the 9-(aminoalkyl)-9,10-dihydroanthracene (DHA) compounds and their
corresponding diphenylalkylamine (DPA) congeners. Ring-opening of the tricyclic
system uniformly produced decreases in affinity for both 5-HT2A and H1 receptors. No
DPA compound exhibited high affinity at 5-HT2A (Ki <100 nM) and only three showed
high affinity for H1 receptors (14, Ki = 64 nM; 15, Ki = 75 nM; 18, Ki = 70 nM). In
contrast, many of the DHA analogs were found to have high affinity at both receptors,
demonstrating that rigid dihydroanthracene is a privileged structure.181
For compounds interacting with the H1 receptor, progressively increasing either
the number of methylene units in the linker or the number of N-methyl groups
consistently retained or enhanced affinity in both the DHA and the DPA series. The H1
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receptor affinity was insensitive to chain length for the unsubstituted amine analogs of
AMDA (1, Ki = 197 nM; 4, Ki = 137 nM; 7, Ki = 175 nM). In contrast, H1 affinity
increased with increasing chain length for both N-methylated (2, Ki = 189 nM; 5, Ki =
47.5 nM; 8, Ki = 3 nM) and N,N-dimethylated analogs (3, Ki = 25 nM; 6, Ki = 6 nM; 9, Ki
= 0.5 nM). For the DHA analogs, N,N-dimethylation and a three-methylene linker was
optimum for H1 affinity (9, Ki = 0.5 nM). The trends in affinity at 5-HT2A are less
uniform. However, increasing the linker length for the N,N-dimethylated DHA analogs
did produce a successive increase in affinity (3, Ki = 540 nM; 6, Ki = 84 nM; 9, Ki = 22
nM).
Like the H1 receptor, the affinity of the DPA compounds for 5-HT2A generally
increased with increasing linker size or degree of N-methylation though, as noted above,
no DPA compound was found to have substantial affinity (Ki < 700 nM) for 5-HT2A. As
observed previously174 for DHA compounds with a one-methylene linker, 5-HT2A affinity
decreased as the degree of N-methylation increased (1, Ki = 20 nM; 2, Ki = 52 nM; 3, Ki =
540 nM). This trend was not observed for the other linker lengths where N-methylation
showed the tendency to increase affinity. Affinities were more uniform for compounds
with one N-methyl group (2, Ki = 52 nM; 5 Ki = 92 nM; 8, Ki = 13 nM), and for those
with two N-methyl groups, affinity increased with linker length by 25-fold (3, Ki = 540
nM; 6, Ki = 84 nM; 9, Ki = 22 nM). In general, binding affinity for the 5-HT2A receptor is
less sensitive to N-methylation and chain length variation than the H1 receptor.
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Table 5. Observed binding affinities for 9-(aminoalkyl)-9,10-dihydroanthracene (DHA)
and diphenylalkylamine (DPA) analogs at 5-HT2A and H1 receptors.
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—CH3
—CH3
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—H
—CH3
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20b
52b
540b
480b
92 ± 2.8
84 ± 9
32b
13b
22b
4480 ± 300
>10,000
7360 ± 1691
>10,000
1500 ± 163
1640 ± 172
2590 ± 632
750 ± 79
1150 ± 120

197 ± 67
189 ± 28
25 ± 4
137 ± 47
48 ± 7
6 ± 0.5
175 ± 59
3 ± 0.3
0.5 ± 0.07
>10,000
>10,000
5170 ± 750
2760 ± 310
60 ± 5
75 ± 6
1670 ± 180
390 ± 29
70 ± 5

Standard errors typically range between 15-25% of the Ki value. bFrom Runyon, et al., 2001.174
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Figure 10. 3D bar graphs showing the affinities at 5-HT2A and H1 for the a) 9-(aminoalkyl)-9,10-dihydroanthracene (DHA) and b)
diphenylalkylamine (DPA) analogs shown in table 5.
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3.2.2 Modeling Receptor-Ligand Interactions: H1 and 5-HT2A Receptor Models
When considering the selectivity of a particular ligand for one receptor versus
another, it is useful to analyze the differences in amino acids that comprise the binding
sites of the two receptors. The alignment of the human H1 and 5-HT2A receptor sequences
with that of human 2-AR is presented in Figure 11. The H1 receptor is phylogenetically
related to the 5-HT2 receptor subtypes, with high sequence homology specifically in the
transmembrane region.182 Based on the primary sequences, binding site analysis of both
5-HT2A and H1 receptors indicates that the major variations in amino acid constitution
occur at positions 3.33, xl2.52, xl2.54, 5.39, 5.42, 6.55 and 7.35 (Figure 11). Differences
in steric and electrostatic side chain properties at these and other positions are likely
responsible for ligand selectivity of the two receptors. The H1 receptor amino acid residue
K1915.39, not commonly found at this position among aminergic GPCRs, could be
potentially exploited for the design of highly selective H1 ligands. The three-dimensional
arrangement of these residues is shown in Figure 12. The residues that are conserved
between H1 and 5-HT2A are those that tend to be highly conserved among all aminergic
GPCRs. These residues, primarily located in the inner region of the binding cavity,
include W3.28, the amine counter-ion D3.32, S3.36 and T3.37, the „aromatic cluster‟ residues
W6.48, F6.52, and Y7.43 (an H-bonding partner for D3.32).
Models of human H1 and 5-HT2A receptors were generated with the MODELLER
program using a high-resolution crystal structure of the human β2-adrenergic receptor as a
template. Inspection of putative receptor binding sites and ligand binding modes in our
homology models (Figure 13) indicate two common interactions that occur for each of
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the compounds at both 5-HT2A and H1 receptors: 1) The highly conserved aspartic acid
residue at position183 3.32 (H1, D1073.32; 5-HT2A, D1553.32) is able to interact with the
protonated amine of the docked ligand; and 2) Hydrophobic residues present in TM6
comprising the aromatic cluster184 are able to interact with the aromatic rings of ligand. In
other binding site locations, variability of amino acid residues at equivalent positions in
the H1 and 5-HT2A influence the way the aromatic rings are oriented in the receptor,
which in turn provide an explanation for the observed differences in affinity for AMDA
and its analogs with varying chain lengths. The presence of hydrophobic residues
surrounding the conserved D3.32 in H1 and in 5-HT2A, together with the aromatic cluster
region in H1 and in 5-HT2A, provide sites of favorable interaction with the ligands for
each receptor.
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Figure 11. Alignment of the human β2-adrenergic, H1 and 5-HT2A receptor sequences.
Sequence positions highlighted in pink indicate highly conserved amino acids among the
Class A GPCR family which serve as reference positions in the BallesterosWeinstein153numbering system. The traditional numbering shown corresponds to the H1
(top) and 5-HT2A (bottom) sequences. β2-Adrenergic residues highlighted in purple
indicate positions in the third intracellular loop that were mutated to glycine in the H1 and
5-HT2A sequences; these were retained in subsequent H1 and 5-HT2A models. Other
residues highlighted in the β2-AR sequence represent the binding site and are those which
are within 5.0 Å of the carazolol ligand bound in the 2AR. The residue color indicates
the degree of similarity at a particular position as defined by the Gonnet PAM250
similarity matrix (green = identical; yellow = strong or weak conservation; red = no
conservation). The figure was created using ALSCRIPT.185
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3.2.3 Binding Mode Analysis
Compounds listed in Table 5 were docked into the receptor binding sites of the H1
and 5-HT2A receptor models using an automated docking routine GOLD. The GOLD
scoring function (steric and electronic interactions) was used to select the favored ligand
conformation. In addition, we carried out HINT163 (Hydropathic INTeraction) analysis to
characterize the nature of the binding site interactions. HINT is a free-energy-based
method that considers atom-atom interactions in a bimolecular complex using a
parameter set derived from octanol/water partition coefficients.186 Modeling observations
indicate that the compounds prefer to be oriented within the binding pockets of the two
receptor models in similar but distinct binding modes (Figure 13). The well-known
aspartate D3.32 residue was found to interact with the basic amine in both receptors for
each docked ligand, and the ligand aromatic rings were consistently oriented in the
binding site surrounded by TM4, TM5 and TM6. In general, for the short-chain linker
ligands there is a relatively small amount of ligand surface area that may interact with the
surrounding hydrophobic environment in the binding pocket, accounting for the observed
decreased affinity of these compounds at both 5-HT2A and H1. However, for AMDA (1),
the observed high affinity could be due to the presence of an alternate binding mode.170
The tricyclic DHA ring system in 9 showed strong hydrophobic interactions
(Y1083.33, L1634.61, F168xl2.38, F1905.38 and F4356.55), with the phenyl rings oriented
toward TM5 and the aliphatic linker located deep in the H1 binding pocket. In contrast, in
the 5-HT2A model, 9 is oriented such that the phenyl rings are facing TM6 (F3396.51,
F3406.52 and N3436.55) and the aliphatic linker is positioned closer to EL2 (Figure 13a and
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13d). For both H1 and 5-HT2A, the compound with the longest linker and highest degree
of methylation (9) was found to have the greatest (H1) or one of the highest (5-HT2A)
affinities among the compounds tested. The methylene linkers in the H1 receptor are able
to interact with residues L1043.29 and Y4316.51 which may explain the comparatively
higher affinity of 9 for H1 than for 5-HT2A. Further, the observed differences in ligand
orientation within the receptor binding site can account for the preference for Nmethylation at H1, with the methyl groups more closely surrounded by hydrophobic
residues as compared to 5-HT2A (Figure 13a and 13d).
For the unbridged DPA analogs, the increased conformational flexibility (as
compared to DHA) and intramolecular steric repulsion produce a twisted ring orientation.
This results in more unfavorable receptor-ligand interactions (steric clashes and polarnonpolar interactions) involving the ring system and the surrounding residues (Figure 13b
and 13e) which may explain the generally low affinity of compound in DPA series as
compared to DHA series.
HINT hydropathy interaction analysis provided additional support for the
proposed orientation of the ligands in the binding pocket. Figure 14 shows the HINT
maps generated for compound 9 (which has highest affinity for both receptors) in the
binding sites of the H1 and 5-HT2A receptors. In each case the tricyclic ring system fits
into the hydrophobic „aromatic cluster‟ while the amine group faces D1073.32 and is
stabilized by both ionic and hydrogen bonding interactions. However, both the aliphatic
linker region and the N-methyl groups engage in more extensive hydrophobic interactions
in H1 than in 5-HT2A.

49

In addition, the receptor-ligand complexes described here are in general
agreement with other studies that have implicated residues that contribute to an
antagonist binding site in H1 and 5-HT2A.170,187,188 Besides the several key residues that
have been reported by site-directed mutagenesis studies in H1 receptor models189
(W1584.56, F4246.44, W4286.48, F4326.52 and F4356.55) and 5-HT2A receptor models190
(F2435.47, W3366.48, F3396.51, F3406.52), we found that Y1083.33 was oriented to favorably
interact with ligands in the binding pocket of the H1 receptor, and the cognate residue
V1563.33 for the 5-HT2A receptor. The differences in the stereoelectronic character of
these residues likely contribute to the differences in the way the ligand binds to these
receptors, and consequently the observed differences in binding affinity.
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Figure 12. Illustration of the differences in binding site residue composition of the H1
and 5-HT2A receptors. Residues are truncated at the C carbon atom (ball-and-stick
representation) and are colored based on residue similarity as described in figure 11. For
those positions whose residue identity differs, the H1 residue is listed first, followed by
the 5-HT2A residue.
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a.

b.

c.

d
d

e

f

Figure 13. Docked receptor-ligand complexes. The H1 receptor model with compounds a) 9, b) 18 and c) 1. The 5-HT2A receptor model with compounds
d) 9, e) 18 and f) 1. Residues within 5 Å of the bound ligand are displayed.
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a.

b.

Figure 14. HINT interaction maps for compound 9 in a) 5-HT2A and b) H1 binding sites.
Regions of favorable hydrophobic (green) and polar (magenta) interactions are shown as
contours.
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3.2.4 Chemistry
9-Aminomethyl-9,10-dihydroanthracene (1) was reported by our group in the
past.173

(9,10-Dihydroanthracen-10-yl)-N-methylmethanamine

(2)

and

(9,10-

dihydroanthracen-10-yl)-N,N-dimethylmethanamine (3) were prepared by reduction
(BH3•THF) of amides 44 and 45 obtained by the treatment of the acid chloride of 43 with
methyl or dimethylamine174 (Scheme 1). 2-(9,10-Dihydroanthracen-9-yl)ethanamine (4)
was prepared from 2-(anthracen-9-yl)ethanamine (48). The condensation of 9anthraldehyde

(46)

with

nitromethane

in

methylene

chloride

gave

9-(2-

nitrovinyl)anthracene (47)191 which was reduced to 2-(anthracen-9-yl)ethanamine (48)
using LiAlH4/THF. The target molecule i.e., 4 was then prepared through middle ring
reduction

using

sodium

metal

in

liquid

Dihydroanthracen-9-yl)-N-methylethanamine

ammonia192
(5)

was

(Scheme
synthesized

2).

2-(9,10-

using

9-

hydroxymethylanthracene (49) as the starting material. Bromination193 followed by
cyanation194 of the alcohol gave 2-(anthracen-9-yl)acetonitrile (51) which was further
hydrolyzed to the corresponding acid 52. Anthracene ring reduction using sodium metal
in 1-pentanol gave 2-(9,10-dihydroanthracen-9-yl)acetic acid (53). Sequential conversion
of the acid 53 to its amide 54 via the chloride, followed by reduction gave the target
molecule 5 (Scheme 3). 2-(9,10-Dihydroanthracen-9-yl)-N,N-dimethylethanamine (6)
was prepared by reductive amination195 of 2-(9,10-dihydroanthracen-9-yl)acetaldehyde
(57) obtained by the oxidation of 2-(9,10-dihydroanthracen-9-yl)ethanol (56)196 (Scheme
4). 3-(9,10-Dihydroanthracen-9-yl)propan-1-amine (7), 3-(9,10-dihydroanthracen-9-yl)N-methylpropan-1-amine

(8),

3-(9,10-dihydroanthracen-9-yl)-N,N-dimethylpropan-1-
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amine (9) were prepared by reduction (BH3•THF) of amides 63, 64 and 65 obtained by
treatment of the acid chloride of 3-(9,10-dihydroanthracen-9-yl)propanoic acid (62)197
with ammonia gas, methylamine and dimethylamine, respectively (Scheme 5). 2,2Diphenylethanamine (10) was commercially obtained. N-methyl-2,2-diphenylethanamine
(11) was obtained by the N-methylation of the respective amine 66 as reported198
(Scheme 6). Compounds N,N-dimethyl-2,2-diphenylethanamine (12) and N-methyl-3,3diphenylpropan-1-amine (14) were obtained commercially. 3,3-Diphenylpropan-1-amine
hydrochloride (13) was obtained in salt form from commercially available 3,3diphenylpropan-1-amine.

N,N-Dimethyl-3,3-diphenylpropan-1-amine

(15)199

was

synthesized by reductive amination of 3,3-diphenylpropanal (68) obtained by the
oxidation of

commercially available 3,3-diphenylpropanol (67) using Dess-Martin

reagent (Scheme 7). 4,4-Diphenylbutan-1-amine (16)200 was prepared by the BH3•THF
reduction of 4,4-diphenylbutyronitrile (71) that was obtained from potassium
amide/liquid ammonia solution of diphenylmethane (69) by alkylation with
bromopropionitrile201 (Scheme 8). N-Methyl-4,4-diphenylbutan-1-amine (17) and N,Ndimethyl-4,4-diphenylbutan-1-amine (18) were prepared by reduction (BH3•THF) of
amides 75 and 76 obtained by treatment of the acid chloride of 4,4-diphenylbutyric acid
(73)202 with methylamine and dimethylamine, respectively. The intermediate compound
73 was obtained from treatment of commercially available lactone 72 with benzene in the
presence of anhydrous aluminum chloride (Scheme 9).
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3.3 Synthetic Schemes
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44 R1 = H, R2 = CH3
45 R1 = CH3, R2 = CH3
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2 R1 = H, R2 = CH3
3 R1 = CH3, R2 = CH3

Scheme 1. a) n-BuLi, diethyl ether, dry ice; b) SOCl2, reflux; c) methyl or dimethyl
amine, THF, 25 ºC; d) BH3•THF, reflux.
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Scheme 2. (a) CH3NO2; (b) LiAlH4, THF; (c) Na, liquid ammonia.
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Scheme 3. (a) PBr3 , toluene; (b) KCN, DMSO; (c) ethylene glycol, KOH; (d) Na, 1pentanol; (e) SOCl2, benzene, methylamine (2M) THF; (f) BH3•THF, reflux.
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Scheme 4. (a) Na2K silica gel, THF; (b) Dess-Martin (periodinane) reagent, CH2Cl2;
(c) dimethylamine hydrochloride, Ti(OiPr)4, NEt3, abs EtOH, NaBH4.
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63 R1 = R2 = H
64 R1 = H, R2 = CH3
65 R1 = CH3, R2 = CH3

7 R1 = R2 = H
8 R1 = H, R2 = CH3
9 R1 = CH3, R2 = CH3

Scheme 5. (a) i. KOC(CH3)3 ii. acrylonitrile, t-butyl alcohol, iii. NH4OH, Zn dust,
hydrochloric acid reflux; (b) Na, 1-pentanol, reflux, 10 min; (c) SOCl2, reflux, 2 hr; (d)
NH3 or methylamine or dimethylamine, THF, 25 ºC; (e) BH3•THF, reflux, 6 hr.
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Scheme 6. (a) aqueous (37%) formaldehyde, CH3CN, NaBH3CN, glacial acetic acid,
(2N) KOH, Et2O.
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Scheme 7. a) Dess-Martin (periodinane) reagent, anhydrous CH2Cl2; (b) dimethylamine
hydrochloride, Ti(OiPr)4, NEt3, abs EtOH, NaBH4.
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Scheme 8. a) K metal, Fe(NO3)3, liq NH3, Et2O; (b) BH3•THF.
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75 R1 = H, R2 = CH3
76 R1 = CH3, R2 = CH3

17 R1 = H, R2 = CH3
18 R1 = CH3, R2 = CH3

Scheme 9. a) anhydrous benzene, AlCl3; (b) SOCl2, benzene; (c) methylamine or
dimethylamine (2M) THF; (d) BH3•THF.
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3.4 Molecular modeling
Homology models were built using the automated software MODELLER (details
in experimental section). The populations of 100 different H1 and 5-HT2A homology
models were generated and subsequently energy minimized. The β2-adrenergic receptor
was used as the template for the generation of models. The selection of the best fit model
in each (H1 and 5-HT2A) case was based on the fitness function values obtained as a result
of docking studies conducted using the automated docking program GOLD details in
experimental). In addition to consistently observed GOLD score, steric and electronic
interactions of the docked poses and reported site-directed mutagenesis data was
considered for the selection of the best fit model. Further, HINT scoring function was
used to characterize the nature of the binding site interactions (details in experimental
section).
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3.5 Conclusions
Within the matrix of compounds synthesized and tested, the N,N-dimethylated
chain lengthened propylene analog of AMDA shows the highest affinity at both 5-HT2A
and H1 receptors (9; 5-HT2A, Ki = 22 nM; H1, Ki = 0.5 nM) and the highest selectivity for
the H1 receptor (44-fold). In addition, removing the conformational restriction of the
dihydroanthracene tricyclic system is detrimental to the ligand affinity for both 5-HT2A
and H1 receptors. Structure-affinity relationships among these compounds show that Nalkylation either decreases or has little effect on 5-HT2A affinity. In the case of
compounds with propylene linker (7, 8 and 9), all have relatively high affinity for the 5HT2A receptor and are less sensitive to the degree of N-alkylation. In addition, the ringopening of the dihydroanthracene system to diphenyl system is generally unfavorable for
the affinity at both 5-HT2A and H1 receptors. Hydropathic analysis of the modeled
complexes supports the proposed role of the TM6 aromatic cluster in directing binding.
The proposed differences in the binding pocket of H1 (Y1083.33) and 5-HT2A (V1563.33)
may determine the way ligands bind, which in turn determine the selectivity of the
ligands for each of two receptors. These preliminary modeling results provide a
qualitative understanding of how AMDA analogs might interact with the 5-HT2A and H1
receptors. This study also provides potential insight into the mechanisms by which
differences in the structures of the receptor and ligand determine the receptor selectivity.
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RING-ANNULATED AND N-SUBSTITUTED ANALOGS OF AMDA AS
STRUCTURAL PROBES FOR 5-HT2A AND H1 RECEPTORS

4.1 Introduction
In the past few years, much information has been generated about the 5-HT2
receptor and its subtypes.3,49 However, it is still not completely clear how serotonergic
ligands (agonists, partial agonists and antagonists) including 5-HT itself interact with the
receptors. In the absence of a crystal structure for the 5-HT2 receptor family, models
generated from a representative GPCR such as rhodopsin or a β-adrenoceptor are used to
study possible drug-receptor interactions.51,171,203 We have previously synthesized and
tested many analogs of the selective 5-HT2 antagonist 9-aminomethyl-9,10dihydranthracene (AMDA). Modeling investigations of AMDA and its analogues have
provided some insight into the possible ligand-receptor interactions responsible for their
affinities at the 5-HT2A and H1 receptors.170,204,205 Literature studies involving H1
antagonists show that diphenhydramine-like structures are the most investigated series of
anti-H1 active structures.107 The results of the quantitative structure-activity relationship
(QSAR)206 studies of these series of compounds suggest that the major characteristics for
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H1 activity are high lipophilicity of an aromatic group, a given distance between a
hydrophobic region and observed ammonium ion and a region of relatively large “bulk
acceptance” around the ammonium ion. In order to further explore receptor binding site
dimensions, we synthesized and tested N-substituted and ring-homologated analogues of
AMDA which can in turn also serve as structural probes to determine the preferred ligand
orientations, ligand-receptor interactions and predict the dimensions of the binding site.

4.2 Substituted Phenylalkylamine Analogs of AMDA as Structural Probes
Molecular modeling studies conducted by us suggested that, all the AMDA
analogs are oriented in a similar fashion but exhibit a different binding mode for 5-HT2A
and H1 receptors.205 In both cases, the tricyclic ring system prefers a hydrophobic core
surrounded by TM 4, 5, and 6 whereas the basic amine-bearing end is oriented toward
TM3. In accordance with the existing trend for various class of antihistamines,107 it was
observed that N-alkylation is favorable for the H1 receptor affinity among AMDA
analogs. However, in case of 5-HT2A receptor an opposite trend was observed in which
N-alkylation led to decreases in the binding affinity.

As mentioned above, we

synthesized and tested N-phenylalkylamine analogs of AMDA (19-22, Figure 15) to
further explore the bulk tolerance at this portion of the binding site. Compound 19 was
previously synthesized in our group. The observed affinity data for these compounds
showed that these compounds had low affinity (Ki = 365 to 710 nM) at 5-HT2A and H1
(Ki = 223 to 964 nM) receptors. The slight variation in the binding affinity values for the
5-HT2A receptor corresponded to the previously observed trend. However, it was
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surprising that phenylalkyl substitution at the basic amine greatly reduces affinity at the
H1 receptor (20, Ki = 242 nM, 21, Ki = 223 nM, 22, Ki = 964 nM), since both classical
and tricyclic antihistamines often have very bulky amine substituents. 107 The results
obtained suggest the possibility that the basic amine in the N-phenylalkyl AMDA analogs
bind in a different environment as compared to the diphenhydramine series and tricyclic
antihistamines. The proposed orientation of the N-phenylalkyl substituent within the 5HT2A and H1 receptor binding site is shown in Figure 16a and 16b.
In addition, the synthesis and testing of the quaternary ammonium salt of AMDA
(23) showed substantially higher affinity for H1 receptor (Ki = 70 nM) as compared to 5HT2A receptor (Ki = 4000 nM). The observed affinity for the H1 receptor could be due to
the presence of Y6.51 in the binding site that forms a π-cation bond207 with the
quaternary ammonium ion in the H1 receptor but not in the 5-HT2A receptor (Figure 17),
further suggesting the possibility of a more hydrophobic binding site environment in H 1
as compared to 5-HT2A

4.3 Ring-annulated Analogs of AMDA as Dimensional Probes
The concept of using ring-annulated or so called “stretched-out” analogues of
high affinity ligands as dimensional probes has been reported but not widely
employed.208 By carrying out systematic ring annulation and substitution one can infer
information about the dimensions of the binding site.209-211 AMDA and its analogs
contain a rigid tricycyclic scaffold. Previously conducted SAR studies170 of substituted
AMDA analogs by us have indicated that there may be a great deal of steric tolerance
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around this tricyclic ring system. However, the large substituents examined to date have a
high degree of rotational freedom due to alkyl chain flexibility. In order to construct a
rigid and elongated structure we decided to expand the tricyclic ring system with fused
aromatic rings (Figure 15). The expansion of the AMDA pharmacophore by benzene
fusion will provide dimensional probes which can extend beyond the existing site and
may permit interactions with additional binding site residues. The initial compound that
we attempted to synthesize and test was tetracene 25. However, the synthetic
methodology chosen for 25 gave a mixture (75:25) of isomers of tetraphene 24 and
tetracene 25 respectively (Scheme 12). The binding affinity data obtained for this mixture
had the Ki value of 10 nM (5-HT2A). Thus it was concluded that at least one of the
isomers binds with high affinity. Based on our previous SAR study experience we
synthesized the ring substituted methoxy-analogue 26 of the expanded AMDA structure
with a similar procedure. The attempted synthesis (Scheme 12) gave a mixture of two
isomers 26 and 27. Due to the challenges faced in the final cyclization step and difficulty
in the separation of products, the reaction gave a very low yield of the final product. The
purification of the reaction mixture resulted in the separation of only the major isomer
i.e., (26) whose binding affinity was determined. The binding affinity data showed that
methoxy-substituted isomer 26 had reasonable affinity (Ki = 21 nM) for the 5-HT2A
receptor while possessing very low affinity for H1 receptor (Ki = 2640 nM). In order to
further confirm the possibility that a single isomer is responsible for high affinity at 5HT2A, the synthesis of compound 25 was carried out by another group member (S. Peddi)
via an unambiguous cyclization route. The binding studies of compound 25 indicated that
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it had no affinity for 5-HT2A receptor (Ki = >10,000 nM). These results indicate the
possibility of an isomer having a pharmacophore features similar to 26 to be responsible
for the affinity of the ligand.
H
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N

H
N

2

3
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Ki (5-HT2A) - 400 ± 34 nM
(H1)
- 242 ± 27 nM

Ki (5-HT2A) - 721 nM
(H1)
- NA

H3C
CH3
N
CH3

H
N
4

22
Ki (5-HT2A) - 365 ± 17 nM
(H1)
- 964 ± 150 nM

H2N

21

H2N

23
Ki (5-HT2A)a - 4000 nM
(H1)
- 70 ± 10 nM
H2N

Ki (5-HT2A) - 422 ± 5 nM
(H1)
- 223 ± 128 nM

OCH3

24

H2N
OCH3

25
Ki (5-HT2A) - >10,000 nM

26

27

Ki (5-HT2A) - 21 ± 0.5 nM
(H1)
- 2640 ± 530 nM

Figure 15. Binding affinity data of AMDA analogs as molecular probes. aFrom Runyon,
et al., Biorg. Med. Chem. Lett. 2001, 11, 655-688.174

4.4 Molecular Modeling studies
The generation and refinement of the 5-HT2A and H1 receptor homology models
used in the docking studies is described in the experimental section. A virtual library of
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compounds shown in Figure 15 with explicit consideration of stereoisomers was built and
energy-minimized. The structures were then docked into the receptor binding site using
the automated docking program GOLD (experimental section). To begin with, the
structures were docked into the homology model built using 2-adrenergic receptor as the
template. However, the docked poses failed to show the optimum interactions between
the ligand and the binding site residues hence we used the homology models built using
bovine rhodopsin as the template. Visual inspection of docking poses in conjunction with
the ChemScore fitness function was used to select the final solution for each isomer. The
GOLD program used for docking was able to place all the ligands in the previously
predicted binding site (Figures 16-18). In each solution, the ligand ammonium ion
interacts with the D1553.32 residue in the binding site. The tetraphene isomer (24) showed
lipophilic interactions with the hydrophobic residues in the binding pocket (Figure 18). In
the case of the methoxy substituted analog 26, docked pose of both the (R)- and (S)stereoisomer showed additional interactions with hydrogen-bond donating S1593.36 and
S771.35 residues respectively, in the 5-HT2A binding site. The vast difference in the affinity
value of compound 25 (>10,000 nM) and mixture of 24 and 25 (Ki = 10 nM), combined
with the observation that methoxy-substituted compound (26) showed higher affinity (Ki
= 21 nM) suggest that the non-linear tetraphene analogs are responsible for the observed
affinity.
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a.

b.

Figure 16. Proposed binding mode of phenylalkylamine analogs of AMDA in the
binding site of the a) 5-HT2A and b) H1 receptors. Ligands are represented as capped stick
model with compounds 19 (yellow), 20 (orange), 21 (cyan) and 22 (green) respectively.
Residues within 4 Å of the bound ligands are displayed.
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Figure 17. Proposed binding mode of quaternary ammonium salt of AMDA in the
binding site of the H1 receptor. Compound 23 (magenta) is represented as capped stick
model. Residues within 4 Å of the bound ligands are displayed.
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a.

b.

c.

d.

.
Figure 18. Proposed binding mode of isomers of ring-homologated AMDA analogs
a) (R)-26 b) (S)-26 c) (R)-24 d) (S)-24 within the binding site of the 5-HT2A receptor.
Residues within 4 Å of the bound ligands are displayed.
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4.5 Chemistry
Compound 9-(N-benzylaminomethyl)-9,10-dihydroanthracene (19) was reported
by our group earlier.174 The phenylalkyl amines 20, 21 and 22 were prepared by reduction
(BH3•THF) of amides obtained by the treatment of the acid chloride with phenylethyl-,
phenylpropyl and phenylbutyl amine respectively (Scheme 10). Compound 23 was
obtained by the N-methylation of previously synthesized compound 3 using iodomethane
(Scheme 11). In case of ring-annulated analogs, commercially available -bromo-otolunitrile (80) on treatment with DIBAL-H in anhydrous CH2Cl2 and work up using
aqueous HBr gave the aldehyde 81 in quantitative yields.212 Palladium catalyzed crosscoupling of 2-naphthylboronic acid and 6-methoxy-2-naphthylboronic acid with the
aldehyde 81 gave the respective coupled aldehydes 82 and 83. Cyanosilylation of the
aldehydes 82 and 83 using TMSCN gave the cyano trimethylsilyl ether as intermediates,
which were reduced with LiAlH4 to give the respective amino alcohols 84 and 85.
Cyclodehydration of aminoalcohols using methanesulfonic acid gave the isomers of
cyclized products 24, 25 and 26, 27 respectively (Scheme 12).

4.6 Synthetic Schemes
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77 R = - (CH2)2C6H5
78 R = - (CH2)3C6H5
79 R = - (CH2)4C6H5

20 R = - (CH2)2C6H5
21 R = - (CH2)3C6H5
22 R = - (CH2)4C6H5

Scheme 10. (a) SOCl2, benzene; (b) phenylethylamine or phenylpropylamine or
phenylbutylamine; (c) BH3•THF.
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Scheme 11. (a) SOCl2, reflux; (b) dimethylamine, THF, 25 ºC; (c) BH3•THF, reflux; (d)
iodomethane, CH2Cl2.
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Scheme 12. (a) DIBAL-H, CH2Cl2; (b) Pd(PPh3)4, K3PO4, 2-naphthylboronic acid/6methoxy-2-naphthylboronic acid; (c) TMSCN, ZnI2, CH2Cl2, LiAlH4, THF; (d)
CH3SO3H.
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4.7 Conclusions

Overall, our results imply that large rigid ring-annulated AMDA analogs can be
sterically accommodated within the proposed 5-HT2A binding site. It is rather remarkable
that compounds of the dimensions of 24 and 26 bind at all and in fact have very high 5HT2A affinity and a low H1 affinity. There are currently no known rigid ligands that show
the affinity for 5-HT2A receptors and exceed the dimensions of these AMDA analogs. For
example, in case of of tricyclic antidepressants, ergot alkaloids and apomorphine the
longest dimension is equivalent to 3 linearly fused rings. We have chosen to carefully
examine the dimensions of the binding site by elaboration of the tricyclic system with
successive aromatic ring fusions which present a rigid obstacle. Further elaboration of the
AMDA skeleton by benzfusion will create dimensional probes which will extend beyond
AMDA itself and allow access to additional sets of binding site residues. Since both the
tetracene and tetraphene isomers of the unsubstituted ring-annulated AMDA analog show
remarkable differences in binding affinities, we would attempt synthesis of substituted
tetraphen analogs of AMDA by a different synthetic method in the future. Based on the
results obtained, we would also attempt the resolution of enantiomers by HPLC using
chiral column supports. The dimensional probe concept can be exploited further by the
design, synthesis of various substituted benzene fused AMDA analogs. Due to their large
rigid structures these ligands can interact with subtype specific residues which can help to
generate selective agents.
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ENGINEERING A SELECTIVE NON-NITROGENOUS AMINERGIC GPCR
LIGAND

5.1 Introduction.
Over the years, significant progress has been made in the development of novel,
high-affinity ligands for several aminergic GPCRs including those activated by
histamine,107 serotonin213 and dopamine.214 However, there is a lack of truly selective
agonists and/or antagonists for most of these receptors. Development of a selective ligand
in the case of aminergic GPCRs is especially challenging due to the presence of highly
conserved structural features among the members of this class of receptors.134,215,216 In
addition, it is also assumed that due to the presence of these common structural features
the various subtypes exhibit a common mechanism of interaction with their ligands.
Since most aminergic GPCR ligands have a basic amine moiety, this feature was
identified as a crucial component for high-affinity receptor-ligand interaction.57
Systematic mutagenesis studies by various groups have identified negatively charged
Asp3.32 as a counter ion for the basic amine in both agonists and antagonists.217-219
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In the past Glennon et al.213 have reported several successful strategies for the
development of selective serotonergic ligands. However, to-date very few cases are
reported for the receptor structure-based design of a selective ligand. Recently, our group
has reported220 homology modeling studies of the kappa-opioid receptor (KOR) with
salvinorin A, a selective non-nitrogenous KOR agonist. The result of our modeling study
suggests that one of the possible reasons for the salvinorin A‟s high KOR selectivity
could be the absence of the highly conserved Asp3.32-amine interaction that is conserved
among all GPCRs. In addition, the models also indicate the presence of a KOR specific
interaction in the binding site. Also, there have been reports of the binding of some
antagonists with reduced, but still significant, affinity at the Asp-mutated 5-HT1A,221 5HT2A54 and muscarinic acetycholine receptors222 suggesting that it may be possibile to
design a GPCR ligand that does not interact with this aspartate.
As mentioned in our earlier studies, in order to understand how molecules bind
at 5-HT2A and the H1 receptors, we conducted docking studies for AMDA and its analogs
with the homology models of receptors. Continuing our efforts to understand the binding
site interactions and test the utility of our models, we generated a testable hypothesis
about the necessity of the interaction involving the highly conserved Asp3.32 and the basic
amine containing ligands that could possibly lead to a selective GPCR ligand.

5.2 Hypothesis based on the Homology Modeling and Reported Site-Directed
Mutagenesis Studies
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Most of the second-generation H1 antagonists penetrate poorly into the CNS, and
have an improved selectivity profile as compared to first-generation H1 antagonists. It is
observed that the addition of a chemical group that is ionized at physiological pH will
convert a potent sedating H1-antagonist into a less sedating one.223 For example the
oxidation of the terminal alcohol group in hydroxyzine to a carboxylic acid group results
in cetrizine, which is less sedating than the parent compound. However, the precise
structural requirements that contribute to receptor selectivity and affinity are
unknown.224-226 Site-directed mutagenesis studies have revealed that Asp 1073.32 in TM3
is crucial for binding of histamine and nearly all H1 receptor antagonists.6,219 In addition,
mutation analysis of the H1 receptor binding pocket has revealed several residues that are
essential for agonist and antagonist interactions.187,188,227 Of these, Lys1915.39 appears to
be unique to the H1 receptor.189,228
A multiple sequence alignment of TM5 for a set of aminergic GPCRs indicates
that Lys191 is found in the histamine H1 receptor at a position (5.39) near the
extracellular end of the TM5 domain where no charged residue is observed in other
aminergic GPCRs.229 Lys191 is thought to interact with the proximal nitrogen (Nπ) of the
imidazole ring of histamine.229 In addition, it may act as a specific anchor point for
second-generation H1 antagonists containing a carboxylate moiety.187,230 Mutation of
Lys1915.39 (human) and its counterpart Lys2005.39 (guinea pig) to alanine leads to
decreased affinity for histamine (5-fold) and an even higher decrease in functional EC50
value (50-fold). In addition, mutational analysis of the antagonist binding site reveals that
the Lys200Ala mutation results in a 10- to 50-fold loss of affinity for zwitterionic
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antagonists such as acrivastine and cetrizine. The affinities of structural analogs of these
compounds lacking carboxylate group were unaffected by the mutation189 (Figure 19).
Studies involving tricyclic rigid analog olopatadine and its structural analog
doxepin that lacks the carboxylic acid substituent, has shown that the presence of the
carboxylic substituent has no significant effect on wild-type H1 receptor affinity
(increases by ~ 2-fold). However, in the case of the mutant D107A H1 receptor, the
affinity of doxepin deceases significantly (~ 60-fold) as compared to olopatadine (~ 12fold), suggesting that a cationic interaction exists in the binding site in addition to the
hydrophobic interactions. Taking into consideration these findings, we carried out
docking studies of a series of known first and second generation H1 antagonists and
AMDA analogs synthesized in our lab. Binding site analysis from the docked poses of
ligands reveal that AMDA and its analogs may bind in a similar manner to H1
antagonists. The basic amine in each bound ligand is able to interact with the conserved
Asp107.3.32 In addition, the carboxylic acid moiety present on the zwitterionic
compounds (acrivastine and olopatadine) was in a favorable position to interact with
Lys1915.39 in H1 receptor. Based on our docking observations and reported228 mutation
study of Lys5.39, we predicted that in addition to the conserved Asp3.32 interaction and the
overall fit of the ligand in the binding pocket, one of the key interactions for the observed
affinities of the zwitterionic compounds could be the ionic interactions involving the
Lys1915.39 that is unique to the binding site of H1 receptor. Thus we generated a
hypothesis that either one of these two ionic interactions might be sufficient for ligand
affinity. Further, the binding study results6 involving the mutant D107A H1 receptor and
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the drug olopatadine suggested that inspite of mutating the highly conserved D107
residue, olopatadine retains its affinity (Figure 19). Thus in order to test our hypothesis of
possibly substituting the highly conserved Asp3.32 ionic interaction with an equivalent
Lys5.39 interaction we decided to synthesize a compound without the basic amine but
incorporate a carboxylic acid substituent in the compound.

5.3 Strategy for the Design of a Selective H1 Ligand
Taking into consideration our predicted anionic interaction of the carboxyclic acid
substitution on the ligand with the specific Lys1915.39 residue in the binding site of H1
receptor, we decided to synthesize the analog of our earlier obtained lead compound
AMDA. Previously conducted SAR studies170,204 on the AMDA analogs had suggested
that the C-3 position of the DHA core showed high stereo-electronic tolerance. Thus,
initially 3-carboxy-AMDA (28) was synthesized in our laboratory by G. Dewkar and
tested. Given the challenges faced in the cyclization and purification of compound 28, a
parallel effort was made to synthesize carboxylic acid-substituted diarylalkyamine analog
29 (Figure 19). Further in accordance with the affinity data obtained (SAR discussion
below) we attempted the synthesis of the 3-carboxy-AMDA analog 30. In addition, we
intended to synthesize a non-nitrogenous, carboxylic acid-containing analog 34 that could
not interact with the conserved Asp3.32. It was also anticipated that such a compound
would be highly selective for the H1 receptor having removed the one ligand-receptor
interaction common to all aminergic GPCRs. Taking into consideration the difficulties
faced in the synthesis of acid-substituted AMDA, we decided to use a different approach
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for the design of high affinity and selective ligands. We used the “deconstruction”
approach that is similar to the previously reported “deconstruction-reconstructionelaboration” approach for the design of selective 5-HT2 ligands.213 In our approach, we
started with the structure of a lead compound olopatadine (35) and deconstructed its
structure to determine the structural requirements for binding. Then we reintroduced each
structural feature in a rational manner to determine how they influence affinity and
selectivity. In doing so, we first synthesized and tested the tricyclic core of olopatadine
with an acetic acid substitution at C-2 position i.e., compound 31. We then synthesized
compound 32 by the reduction of the ketone functionality. Further, we replaced the
ketone with an olefinic bond to obtain 33. However, we found that none of these
compounds i.e., 31, 32 and 33 bind at 5-HT2A and H1 receptors. Comparing the structure
and binding data of 33 (Figure 19) with lead compound olopatadine (35) and its analog
doxepin (36), we concluded that an alkylamine chain is needed for high affinity at both
receptor types and acid substitution might determine selectivity. Hence in the final step,
we synthesized compound 34 that was structurally analogous to olopatadine with the
exception of basic nitrogen atom.
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Ki (5-HT2A) - 630 nM
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For D107A (H1) - 25 nM

Ki (5-HT2A) - 0.6 nM
(H1)
- 3.3 nM
For D107A (H1) - 190 nM
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N
COOH
N

N

Acrivastine (37)b

Triprolidine (38)b

Ki (H1) - 10 nM
For L200A (H1) - 548 nM

Ki (H1) - 4 nM
For L200A (H1) - 2 nM

Figure 19. Probes for the design of a selective H1 ligand. aFrom Nonaka, et al., Eur. J.

Pharmacol. 1998, 345, 111-117.6 bFrom Weiland, et al., J. Biol. Chem.1999, 274, 2999430000.189
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5.4 Results and discussion
5.4.1 Structure-Affinity Relationship Studies
The modeled orientation of the ligand within the predicted binding site and the
associated receptor-ligand interactions were consistent with the binding affinity data in
Figure 19. The 3-carboxy-AMDA (28) exhibited some affinity for the H1 receptor,
suggesting a possible interaction of the carboxylate substituent with a cationic residue
Lys1915.39 in the H1 binding site. However, the affinity was very low (Ki = 632 nM).
Observation of docked poses indicates that the relatively low affinity of 28 as compared
to AMDA (Ki = 197 nM) could be due to the length of the short linker connecting the
amine with the biaryl moiety, which would prevent compound 28 from adopting a highaffinity conformation in the binding pocket so as to interact with both D(3.32) and
K(5.39). The studies189 involving the H1 antagonist triprolidine (38) and its acidsubstituted analog acrivastine (37) suggest that the presence of a carboxylic group
substituent has little effect on H1 affinity (decreases by 2.5-fold). However, the mutant
K200A H1 receptor showed a decrease in affinity (~ 55-fold), suggesting the possible
cationic interaction of K2005.39 with the carboxylate group of the ligand. Thus, in
comparison to the acrivastine structure to test the possible effect of a larger amine linker
length, we synthesized and tested diarylamine analog 29. Interestingly, it exhibited very
low affinity (Ki = 5950 nM) for the H1 receptor.
From our initial modeling studies, it was rationalized that one possible reason for
the observed lack of affinity could be that the presence of the highly charged carboxylate
group prevents the parent aromatic ring from taking full advantage of the aromatic cluster

80

located on and around the TM5 and 6. In addition, comparison of the docked poses of
compound 29 with acrivastine (37) in our model suggests that in order to take advantage
of the cationic interaction of K(5.39), the carboxylic group substituent should be located
at the 4-position (29, Figure 19) with an extended ethylene linker as in acrivastine. As
stated in our strategy, we then synthesized and tested structural analog of olopatadine
lacking the nitrogen atom. None of the non-nitrogenous carboxylic acid-substituted
analogs 31, 32 and 33 showed affinity for the 5-HT2A receptor, suggesting the importance
of other pharmacophoric features (basic amine) on the molecule for the favorable
interaction in the binding site. Among all of the tested non-nitrogenous compounds with a
rigid tricyclic core, only compound 34 showed moderate affinity at the H1 receptor (Ki =
250 nM) providing support for our proposed hypothesis. In accordance with a previously
reported study6 investigating the binding site interactions of H1 receptor antagonists, one
of the possible reasons for the observed binding affinity of 34 at the H1 receptor is that
the conserved ammonium ion interaction is not essential for the binding. The anionic
interaction of the carboxylate group with K1915.39 on TM5 likely provides an equivalent
electrostatic interaction to that of D1073.32 on TM3. The modest affinity values for
compound 34 can be due to multiple reasons, one of them being the replacement of the
functionally relevant nitrogen atom. Studies relating functional group contributions to
drug-receptor interactions have shown that replacement of a critical charged nitrogen
atom with a neutral carbon atom would result in an average decrease in the actual binding
energy of 11.5 kcal/mol, suggesting that the charged nitrogen group shows a stronger
interaction than the neutral group231 or even a carboxylate group (8.2 kcal/mol) and
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providing a partial explanation for the modest observed affinity of 34. Furthermore, the
proposed K1915.39 residue in the binding site possesses a flexible butylene side-chain
linker providing more rotational degrees of freedom than D1073.32 or most other naturally
occurring amino acids. Thus its interaction with a flexible carboxyl group substituent on
34 is entropically disfavored, leading to decrease in binding affinity.

5.4.2 Modeling interactions
The histamine H1 receptor model was generated by using a β2-adrenergic receptor
crystal structure (β2AR) as the homology modeling template and used to study the ligandreceptor interactions involving acid substituted ligands. The lead compound olopatadine
and its non-nitrogenous analog 34 with precise consideration of stereoisomers, was
sketched, energy-minimized and docked into the receptor binding site (see Experimental
Methods). Visual inspection of docked poses, the GoldScore fitness function and
information from site-directed mutagenesis studies were used to select a solution for each
isomer. The GOLD232 program used for docking was able to place all the ligands in the
previously predicted binding site (Figure 20). In case of olopatadine, both E and Z
isomers show a similar binding mode in the binding site of H1 receptor. The protonated
amine exhibits strong ionic interaction with the D1073.32, while the carboxylate group
simultaneously showed extensive hydrogen bonding/ionic interaction with K1915.39.
Binding site residues T1945.42 and Y1083.33 also form putative hydrogen bonds with the
ligand carboxylate moiety. Both isomers of compound 34 bind in a similar fashion to
olopatadine in the binding cavity with the exception of the ammonium ion interaction.
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The HINT (Hydropathic INTeraction) scoring function was used to further
support the receptor-ligand interactions predicted by the generated conformations of the
ligand using the GOLD docking program. A HINT map was generated (details in
experimental). Figure 21 illustrates the interactions with a HINT map, where the size of
the displayed contour represents the extent of the interaction, and the color represents the
type of interaction between the molecule 34 and the histamine binding site. The tricyclic
ring system of compound 34 with the aliphatic linker fits in the predominantly
hydrophobic pocket formed by Y1083.33, F1903.38, N1985.46, S1113.36 and Y4587.43. In
addition, there is a region of favorable polar interactions surrounding the carboxylate
substituent on the aromatic ring. This carboxylate group engages in favorable polar
interaction with the residue K1915.39 and the neighboring residues Y1083.33 and T1945.42.
The relatively large number of favorable polar and nonpolar interactions could be
responsible for the significant observed affinity of compound 34 for the H1 receptor,
despite the absence of a basic amine moiety.
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a.

b.

c.

d.

Figure 20. Docked poses of a. (E)-olopatadine, b. (Z)-olopatidine, c. (E)-34, d. (Z)-34
in H1 model.
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Figure 21. HINT interaction maps for compound 34 in H1 binding sites. Regions of
favorable hydrophobic (green) and polar (magenta) interactions are shown as contours.
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5.4.3 Chemistry
Compound 28 was synthesized by G. Dewkar in our laboratory. Synthesis of
compound 29 was carried out by standard Wittig reaction following the reported
procedure233 (Scheme 13). The keto ester 87 obtained by the esterification of 4benzoylbenzoic acid (86) was reacted with phosphonium salt followed by the hydrolysis
of the ester side-chain to give intermediate 89. This was further subjected to
hydrogenation to give the final product 29. We were not able to synthesize compound 30
(Figure 19). To begin, an attempt was made to synthesize 34 from dibenz[b,e]oxepin-2acetic acid (31) and the corresponding phosphonium salt prepared from 1-bromo-4methylpenatane and triphenylphosphine.234 A substituted ethyl o-toluate (90) was
brominated with N-bromosuccinimide to provide 91. This intermediate was then
condensed with ethyl 2-(4-hydroxyphenyl)acetate to give crude ester 92 which was
hydrolyzed to the diacid 93. The diacid obtained was cyclized using polyphosphoric acidacetic acid mixture to obtain the product 31 (Scheme 14). Compound 32235 was obtained
by the reduction of ketoacid 31 using Zn-AcOH (Scheme 15). Compound 33 was
obtained by the hydrolysis of 94236, which was obtained by the Wittig reaction using the
reported method236 (Scheme 16). Synthesis of compound 34 turned out to be much more
challenging than expected. As shown in Scheme 18, initial attempts of carrying out
Wittig reaction on the keto acid 31237 and the corresponding ester 35235 failed. Further
attempts to use the Wittig reaction with the oxazoline-protected compound failed due to
the low yield of compound 36236 obtained utilizing 2-methyl-2-aminopropanol for the
formation of oxazole.238 The in situ esterification of the keto acid 31 following the Wittig
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reaction resulted in compound 37; however, the yield was drastically low. The synthetic
Scheme utilized in the preparation of the desired (E,Z)-(11-[4-methylpentylidene]-6,11dihydrobenz[b,e]oxepin-2-acetic acid (34) is illustrated in Scheme 17. In this method,
using 4-(2-hydroxyethyl)phenol instead of 4-hydroxyphenylacetate as the starting
material, the alcohol substituted ketone (98)239 was obtained. The alcohol was protected
using TBDMS240 to give 99 which was then subjected to the Wittig reaction using
LHMDS as a base.241 The deprotection of the compound 100 by TBAF234 followed by
the TEMPO242 oxidation of the alcohol side-chain gave the final product 34.

5.5 Synthetic Schemes
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Scheme 13. (a) CH3OH, H2SO4; (b) Ph3P+-CH2(CH2)2-N(CH3)2Br-, THF, 1.6M n-BuLi;
(c) 1N NaOH, CH3OH; (d) 10% Pd/C, HCl, CH3OH.

87

CO2CH2CH3
a

CO2CH2CH3
b

90

91

CO2CH2CH3

O

Br

92
O

COOH

COOH

c

CO2CH2CH3

COOH

d

O

O

93

31

Scheme 14. (a) NBS, benzoyl peroxide, CCl4; (b) K2CO3, KI,
ethyl 2-(4-hydroxyphenyl)acetate, butanone; (c) aq NaOH, MeOH; (d) PPA, acetic acid.
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Scheme 16. (a) Ph3P+-CH3Br, n-BuLi, THF, p-TsOH, MeOH; (b) 10% NaOH, MeOH.
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Scheme 17. (a) n-BuLi, THF, Ph3P+-CH2(CH2)3-CH(CH3)2 Br-; (b) abs ethanol, H2SO4; (c) (i)
Pyridine, SOCl2, CH2Cl2; (ii) NH2C(Me)2CH2OH , toluene; (iii) SOCl2, CH2Cl2; (d) p-TsOH,
MeOH.
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Scheme 18. (a) NBS, benzoyl peroxide, CCl4; (b) K2CO3, KI, 4-(2-hydroxyethyl)phenol

butanone; (c) aq NaOH, MeOH; (d) acetyl chloride; (e) TFAA, BF 3·OEt2, DCM, NaOH;(f)
TBDMS, imidazole, DMF; (g) LHMDS, Ph3P+-CH2(CH2)3-CH(CH3)2 Br-, THF; (h) TBAF, THF;
(i) NaClO2/TEMPO, NaOCl, MeCN.
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5.6 Conclusions
The results obtained from the binding data and site-directed mutagenesis studies,
supported by the homology modeling studies show that the compound (E,Z)-(11-[4methylpentylidene]-6,11-dihydrobenz[b,e]oxepin-2-acetic acid (34) is a lead for the
design of selective H1 receptor antagonists. The moderate affinity (Ki = 250 nM) and high
selectivity for the H1 vs. 5-HT2A receptor without a basic amine moiety in the ligand
structure imply that the presence of an ionizable functional group (e.g. carboxylate) as a
substituent can replace the basic nitrogen atom essential for the interaction with D3.32 in
H1, and these results may be used in the further development of selective high-affinity H1
ligands. Further, the general approach reported here can be used in the design of selective
GPCR ligands. In continuation of our work, we also would attempt the synthesis of
analog of compound 34 without the carboxylic acid substituent which could serve as a
reference for our proposed hypothesis and also study the effect of Lys5.39 mutation on our
tested ligands.
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SUMMARY

Based on our investigation of the binding site interactions of serotonin 5-HT2A
and histamine H1 receptors with various ligands, we conclude that homology modeling
and ligand docking studies, supported by binding affinity and site-directed mutagenesis
data, can be used to understand the possible ligand-receptor interactions and to generate
reasonable leads for the development of selective high-affinity ligands. Rational SAFIR
studies around the early lead compound AMDA (9-aminomethyl-9,10-dihydroanthacene)
led us to identify a molecule 3-(9,10-dihydroanthrace-9-yl)-N, N-dimethylpropan-1amine (9) with high affinity at both 5-HT2A (Ki = 22 nM) and H1 Ki = 0.5 nM) receptors..
However, the selectivity of this compound with respect to other 5-HT subtypes (5-HT2B,
5-HT4-7) remains to be tested. Further, the molecular modeling indicates the presence of
differing residues at position 3.33 within the binding site of 5-HT2A (V1563.33) and H1
(Y1083.33) receptors and that this difference could play a role in determining the affinity
and selectivity of ligands among these two receptors. SAFIR and modeling observations
suggest that AMDA and its chain-lengthened analogs can serve as effective probes to
investigate the 5-HT2A and H1receptor binding sites.
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The modeling investigations supported by the binding data show that ringannulated AMDA analogs with a methoxy substituent can be used as dimensional probes
to explore the additional binding site interactions. Using this technique (7, 12-dihydro-3methoxytetraphen-12-yl)methanamine (26), a compound with high affinity and
selectivity was identified (5-HT2A Ki = 21 nM; H1 Ki = 2640 nM). In addition,
comparison of the binding site residues between 5-HT2A and H1 receptors and the
reported sequence alignment studies among aminergic GPCRs show that Lys1915.39 is
unique to the H1 receptor. Lys1915.39 is proposed to be able to form an ionic interaction
with the carboxylate group of zwitterionic H1 antagonists (acrivastine and olopatadine)
and

the

designed

compound

(E,Z)-(11-[4-methylpentylidene]-6,11-

dihydrobenz[b,e]oxepin-2-acetic acid (34). Our compound 34 could act as a lead for the
development of non-nitrogenous H1-selective receptor ligands. However, the selectivity
of this compound with respect to other 5-HT subtypes (5-HT2B/2C and 5-HT4-7) remains to
be tested.
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EXPERIMENTALS

7.1 Chemistry
Melting points were determined using a Thomas-Hoover melting point apparatus
and are uncorrected. Nuclear magnetic resonance (1H NMR and 13C NMR) spectra were
obtained with a Varian Gemini 300 MHz spectrometer and chemical shifts are reported in
parts per million (δ), using tetramethylsilane (TMS) as an internal standard. Unless
otherwise mentioned the spectral data corresponds to the free amine using chloroform as
the internal standard. In case of the salt form the respective solvent is mentioned. The
oxalate salts were prepared by dissolving the respective amine in anhydrous acetone; this
mixture was then added to a solution of oxalic acid in anhydrous acetone. Hydrochloride
salts were prepared similarly by addition of anhydrous HCl solution. Elemental analysis
was performed by Atlantic Microlab Inc. (Norcross, GA), and determined values are
within 0.4% of theory (except where indicated). Column chromatography was performed
on silica gel, grade 62, 60-200 mesh, 150 Å (Sigma-Aldrich, MO). Routine thin-layer
chromatography (TLC) was performed on silica gel GHFL (250 microns, 2.5 × 10 cm;
Analtech Inc., Newark, DE). Unless otherwise mentioned, all the reagents and chemicals
were obtained from Sigma-Aldrich, MO.

(9,10-Dihydroanthracen-10-yl)-N-methylmethanamine

hydrochloride

(2).174

BH3•THF complex (1.0 M in THF, 0.51 g, 6.0 mmol) was added in a dropwise manner to
a stirred solution of 44 (0.3 g, 1.2 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.
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The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture
was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture
heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under
reduced pressure. Water was added and the residue was extracted with ether (25 mL).
The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25
mL). The organic layer was washed with water, brine and dried (MgSO4). Removal of
solvent under reduced pressure afforded 2. It was then purified by medium pressure
column chromatography, CH2Cl2/MeOH (9:1) (0.267g, 85%). HCl salt: mp 250 - 252 °C.
1

H NMR (CDCl3): 2.44 (s, 3H), 3.07 (d, J = 7.2 Hz, 2H), 3.97 (d, J = 18.6 Hz, 1H), 4.16

(d, J = 18.6 Hz, 1H), 4.54 (t, J = 8.1 Hz, 1H), 7.27 - 7.50 (m, 8H); 13C NMR (CDCl3): 
34.15, 35.01, 44.16, 52.91, 127.27, 127.92, 128.70, 129.08, 136.51, 137.57. Anal. Calcd
for (C16H17N·HCl·0.25 H2O) C, 72.71; H, 7.05; N, 5.29 Found: C, 72.77; H, 6.98; N,
5.30.

(9,10-Dihydroanthracen-10-yl)-N,N-dimethylmethanamine

hydrochloride

(3).174

BH3•THF complex (1.0 M in THF, 0.51 g, 6.0 mmol) was added in a dropwise manner to
a stirred solution of 45 (0.3 g, 1.19 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.
The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture
was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture
heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under
reduced pressure. Water was added and the residue was extracted with ether (25 mL).
The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25
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mL). The organic layer was washed with water and brine, dried (MgSO4), and
concentrated under reduced pressure to give 3. It was then purified by medium pressure
column chromatography, CH2Cl2/MeOH (9:1) (0.248 g, 88%). HCl salt: mp 248 - 250 °C
1

H NMR (DMSO): 2.72 (s, 6H), 3.36 (d, J = 7.5 Hz 2H), 3.96 (d, J = 18.3 Hz, 1H), 4.21

(d, J = 18.3 Hz, 1H), 4.67 (t, J = 8.1 Hz, 1H); 13C NMR (DMSO):  35.21, 43.06, 44.20,
60.73, 127.23, 128.01, 128.76, 129.08, 136.87, 138.05. Anal. Calcd for (C17H19N·HCl·
0.25 H2O) C, 74.57; H, 7.36, N; 5.11 Found: C, 73.36; H, 7.42; N, 5.03.

2-(9,10-Dihydroanthracen-9-yl)ethanamine oxalate (4).174 Anhydrous ammonia (15
mL) was added to a well stirred solution of compound 48 (0.2 g, 0.9 mmol) dissolved in
THF (5 mL) by using a cold finger under N2 at -78 °C. Sodium metal (0.05 g) was then
added in pieces and the reaction was stirred for 25 min. The mixture was then allowed to
cool to rt and poured into a large excess of NH4Cl solution, then extracted with EtOAc (3
× 25 mL). The combined EtOAc extracts were washed with water, brine and dried
(MgSO4). The solvent was removed under reduced pressure to yield the amine 4 that was
purified by medium pressure column chromatography, CH2Cl2/MeOH (9:1) (0.1 g,
50.0%). Oxalate salt: mp 193-195 °C. 1H NMR (CDCl3): 2.02 (q, J = 7.8 Hz, 2H), 2.7 (t,
J = 7.8 Hz, 2H), 4.02 (t, J = 7.2 Hz, 1H), 3.89 (d, J = 18.3 Hz, 1H) 4.0 (d, J = 18.3 Hz,
1H), 7.1 - 7.3 (m, 8H).

13

C NMR (CDCl3):  34.8, 39.5, 40.1, 45.6, 126.3, 128.1, 136.4,

140.6. Anal Calcd for (C16H17N·C2H2O4) C, 68.99; H, 6.11; N, 4.47 Found C, 68.72; H,
6.26; N; 4.45.
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2-(9,10-Dihydroanthracen-9-yl)-N-methylethanamine oxalate (5). BH3•THF complex
(1.0 M in THF, 0.33 g, 3.96 mmol) was added in a dropwise manner to a stirred solution
of 54 (0.25 g, 0.99 mmol) in anhydrous THF (4 mL) under N2 at 0 °C. The mixture was
slowly warmed to rt and heated at reflux (6 h). The reaction mixture was allowed to cool
to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture heated at reflux (1 h)
and allowed to cool to rt, and the solvent was removed under reduced pressure. Water
was added and the residue was extracted with ether (25 mL). The aqueous portion was
made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The organic layer
was washed with water and brine, dried (MgSO4), and concentrated under reduced
pressure to give the amine as an oil. The oil obtained was purified by medium pressure
column chromatography, CH2Cl2/MeOH (9:1) to yield 17 as an oil (0.2 g, 85%). Oxalate
salt: mp 202 - 205 °C. 1H NMR (CDCl3): 1.81 (q, J = 7.5 Hz, 2H), 2.38 (s, 3H), 2.56 (t, J
= 7.5 Hz, 2H), 3.99 (d, J = 18.3 Hz, 1H), 4.09 (d, J = 18.3 Hz, 1H), 4.0 (t, J = 7.8 Hz,
1H), 7.16 - 7.3 (m, 8H). 13C NMR (CDCl3):  35.3, 36.7, 37.4, 45.4, 50.2, 126.4, 128.1,
136.4, 140.6. Anal Calcd for (C17H19N·C2H2O4·0.25 H2O) C, 68.76; H, 6.52; N, 4.22
Found: C, 68.43, H, 6.35, N, 4.22.

2-(9,10-Dihydroanthracen-9-yl)-N,N-dimethylethanamine oxalate (6). To a stirred
solution of triethylamine (0.18 g, 1.79 mmol) in absolute ethanol was added
dimethylamine hydrochloride (0.14 g, 1.79 mmol), titanium isopropoxide (0.51 g, 1.79
mmol) and compound 57 (0.2 g, 0.89 mmol). The reaction mixture was stirred at rt for 12
h. Sodium borohydride (0.1 g, 2.68 mmol) was added to this mixture and stirring was
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continued for a further 12 h. The reaction was quenched by pouring the mixture into
aqueous ammonia (20 mL, 2 N) and the resulting precipitate was filtered and washed
with CH2Cl2 (3 × 20 mL). The filtrate was collected and the mixture was extracted with
CH2Cl2. The CH2Cl2 portion was dried (MgSO4) and concentrated under reduced pressure
to obtain viscous yellow oil that was purified by medium pressure column
chromatography, CH2Cl2/MeOH (9:1) to yield 6 (0.12 g, 55%). Oxalate salt: mp 184 186 °C. 1H NMR (CDCl3): 1.83 (q, J = 7.5 Hz, 2H), 2.26 (s, 6H), 2.33 (m, 2H), 3.94 (d, J
= 18.6 Hz, 1H), 4.14 (d, J = 18.6 Hz, 1H), 4.1 (t, J = 7.2 Hz, 1H), 7.1 - 7.3 (m, 8H). 13C
NMR (CDCl3):  32.3, 40.4, 45.3, 52.2, 56.2, 126.8, 128.7, 138.4, 140.1. Anal Calcd for
(C18H21N·C2H2O4·0.5 H2O) C, 68.55; H, 6.90; N, 3.99 Found: C, 68.76, H, 6.72, N, 3.96.

3-(9,10-Dihydroanthracen-9-yl)propan-1-amine oxalate (7). BH3•THF complex (1.0
M in THF, 0.17 g, 1.98 mmol) was added in a dropwise manner to a stirred solution of 63
(0.1 g, 0.397 mmol) in anhydrous THF (4 mL) under N2 at 0 °C. The mixture was slowly
warmed to rt and heated at reflux (6 h). The reaction mixture was allowed to cool to rt,
and HCl (6.0 M, 3 mL) was added with caution. The mixture heated at reflux (1 h) and
allowed to cool to rt, and the solvent was removed under reduced pressure. Water was
added and the residue was extracted with ether (25 mL). The aqueous portion was made
basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The organic layer was
washed with water and brine, dried (MgSO4), and concentrated under reduced pressure to
give 7 as an oil. It was then purified by medium pressure column chromatography,
CH2Cl2/MeOH (9:1) (0.07 g, 75%). Oxalate salt: mp 210 - 212 °C. 1H NMR (DMSO):
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1.49 (m, 2H), 1.56 (m, 2H), 2.69 (t, J = 7.2 Hz, 2H), 3.92 (t, J = 6.3 Hz, 1H), 3.89 (d, J =
18.6 Hz, 1H), 4.0 (d, J = 18.6 Hz, 1H), 7.1 - 7.3 (m, 8H).

13

C NMR (DMSO):  25.92,

34.35, 35.02, 35.08, 46.48, 50.1, 128.3, 128.5, 136.7, 140.6. Anal Calcd for
(C17H19N·C2H2O4) C, 69.71; H, 6.47; N, 4.28 Found: C, 69.47; H, 6.35; N, 4.22

3-(9,10-Dihydroanthracen-9-yl)-N-methylpropan-1-amine oxalate (8). BH3•THF
complex (1.0 M in THF, 0.161 g, 1.88 mmol) was added in a dropwise manner to a
stirred solution of 64 (0.1 g, 0.376 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.
The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture
was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture
was heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under
reduced pressure. Water was added and the residue was extracted with ether (25 mL).
The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25
mL). The organic layer was washed with water and brine, dried (MgSO4), and
concentrated under reduced pressure to give 8 as an oil. It was then purified by medium
pressure column chromatography, CH2Cl2/MeOH (9:1) (0.075 g, 80%). Oxalate salt: mp
148 - 150 °C. 1H NMR (DMSO): 1.53 (m, 4H), 2.44 (s, 3H), 2.78 (t, J = 7.2 Hz, 2H), 3.92
(t, J = 7.4 Hz, 1H), 4.02 (d, J = 18.6 Hz, 1H), 3.8 (d, J = 18.6 Hz, 1H), 7.1-7.3 (m, 8H).
C NMR (DMSO):  24.3, 33.1, 34.25, 35.01, 46.37, 48.66, 128.38, 128.55, 136.72,

13

140.5. Anal Calcd for (C18H21N·C2H2O4) C, 70.36; H, 6.79; N, 4.10 Found: C, 70.44; H,
6.87; N, 4.11.

98

3-(9,10-Dihydroanthracen-9-yl)-N,N-dimethylpropan-1-amine oxalate (9). BH3•THF
complex (1.0 M in THF, 0.15 g, 1.75 mmol) was added in a dropwise manner to a stirred
solution of 65 (0.1 g, 0.35 mmol) in anhydrous THF (4 mL) under N2 at 0 °C. The
mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture was
allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture was
heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under
reduced pressure. Water was added and the residue was extracted with ether (25 mL).
The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25
mL). The organic layer was washed with water and brine, dried (MgSO4), and
concentrated under reduced pressure to give 9 as an oil. It was then purified by medium
pressure column chromatography, CH2Cl2/MeOH (9:1) (0.078g, 85%). Oxalate salt: mp
1

H NMR (CD3OD): 1.63 (s, 4H), 2.71 (s, 6H), 2.94 (s, 2H), 3.87 (d, J = 18.6 Hz, 1H),

3.89 (t, J = 7.2 Hz, 1H), 4.1 (d, J = 18.6 Hz, 2H), 7.14 -7.28 (m, 8H).

13

C NMR

(CD3OD):  22.5, 33.8, 34.7, 42.1, 57.5.2, 126.2, 127.8, 136.3, 139.9. Anal Calcd for
(C19H23N·C2H2O4) C, 70.96; H, 7.09; N, 3.94 Found: C, 70.77; H, 7.05; N, 4.04.

N-Methyl-2,2-diphenylethanamine oxalate (11). Sodium cyanoborohydride (0.5 g, 8
mmol) was added to a stirred solution of 2,2-diphenylethanamine 66 (1 g, 5.0 mmol) and
37% aqueous formaldehyde (2.0 mL, 25 mmol) in acetonitrile (15 mL). A vigorous
exothermic reaction followed and a dark residue was separated. The reaction mixture was
stirred for 15 min, and then glacial acetic acid was added dropwise until the solution
tested neutral on wet pH paper. Stirring was continued for an additional 45 min, glacial
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acetic acid being added occasionally to maintain the pH near neutrality. The solvent was
evaporated at reduced pressure, and 2 N KOH (20 mL) was added to the residue. The
resulting mixture was extracted with ether (3 × 20 mL). The combined ether extracts
were washed with 0.5 N KOH (20 mL) and then extracted with 1N HCl (3 × 10 mL). The
acid extracts were combined and neutralized with solid KOH and then extracted with
ether (3 × 20 mL). The combined ether extracts were dried (MgSO4) and evaporated in
vacuum to provide yellow oil. The resulting yellow oil was purified using medium
pressure chromatography, CH2Cl2/MeOH (9:1) to yield 11 (0.45 g, 40%). Oxalate salt:
mp 150 - 152 °C. 1H NMR (CDCl3): 2.36 (s, 3H), 3.01 (d, J = 8.1 Hz, 2H), 4.28 (t, J = 8.1
Hz, 1H), 7.2 - 7.4 (m, 10H).

13

C NMR (CDCl3):  40.3, 51.8, 62.3, 123.0, 123.8, 124.2,

141.5. Anal Calcd for (C15H17N·C2H2O4) C, 68.29; H, 6.67; N, 4.50 Found: C, 67.89; H,
6.35; N, 4.64.

3,3-Diphenylpropan-1-amine hydrochloride (13). Commercially available 3,3diphenylpropan-1-amine (0.1 g) was dissolved in anhydrous acetone (4 mL). Anhydrous
HCl (1.2 mL) was added to this solution and refrigerated. The solution was filtered and
dried under vacuum to yield 13 (0.08 g, 90%). HCl salt: mp 216 - 218 °C. (lit246 218 219 °C). 1H NMR (CDCl3): 2.36 (q, J = 7.8 Hz, 2H), 2.63 (t, J = 8.4 Hz, 2H), 4.13 (t, J =
7.8 Hz, 1H), 7.17 - 7.30 (m, 10H). 13C NMR (CDCl3):  33.1, 38.37, 48.0, 127.0, 128.2,
129.2, 144.6. Anal Calcd for (C15H17N·HCl) C, 72.71; H, 7.32; N, 5.65 Found: C, 72.75;
H, 7.36; N, 5.60.
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N,N-Dimethyl-3,3-diphenylpropan-1-amine

oxalate

(15).

To

a

solution

of

triethylamine (0.96 g, 9.5 mmol) in absolute ethanol (10 mL) was added dimethylamine
hydrochloride (0.77 g, 9.5 mmol), titanium isopropoxide (2.69 g, 9.5 mmol), and
compound 68 (1 g, 4.7 mmol). Reaction mixture was stirred at rt for 12 h. To this mixture
NaBH4 (0.266 g, 7.05 mmol) was added and stirring was continued for 12 h. The reaction
was quenched by pouring the mixture into ammonia (30 mL, 2 N) solution. The resulting
precipitate was filtered and washed with CH2Cl2 (3 × 20 mL). The filtrate was collected
and the mixture was extracted. The CH2Cl2 portion was dried (MgSO4) and concentrated
under reduced pressure to give viscous yellow oil. The resulting yellow oil was purified
using medium pressure chromatography, CH2Cl2/MeOH (9:1) to obtain 15 (0.25 g, 22%).
Oxalate salt: mp 150 - 152 °C. 1H NMR (CDCl3): 2.52 (m, 2H), 2.85 (s, 6H), 3.0 (m, 2H),
4.2 (t, J = 7.4 Hz, 1H), 7.2 - 7.4 (m, 10H). 13C NMR (CDCl3):  32.2, 45.8, 50.6, 58.3,
126.3, 128.2, 129.1, 143.1. Anal. Calcd for (C17H21N·C2H2O4·0.25 H2O) C, 67.43; H,
7.14; N, 4.13 Found: C, 67.73; H, 6.97; N, 4.11.

4,4-Diphenylbutan-1-amine hydrochloride (16).247 A 1.0 M solution of BH3•THF
complex (0.386 g, 4.5 mmol) was added at 0 °C to a well stirred solution of compound 71
(0.2 g, 0.9 mmol) in anhydrous THF (5 mL). The solution was brought to rt and then
heated to reflux (8 h) and cooled. 6.0 M HCl (2 mL) solution was added cautiously to the
reaction mixture, and continued to reflux (1 h). The reaction mixture was cooled and the
solvent was removed under reduced pressure resulting in a white residue. Water (10 mL)
was added to this residue followed by extraction with EtOAc (2 × 15 mL). The aqueous
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phase was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The
combined CH2Cl2 extracts were washed with water, brine and dried (MgSO4). The
solvent was removed under reduced pressure to give the amine 16 (0.17 g, 85%) as oil.
HCl salt: mp 198 - 200 °C. 1H NMR (CDCl3): 1.45 (m, 2H), 2.1 (m, 2H), 2.7 (t, J = 7.8
Hz, 2H), 4.0 (t, J = 7.8 Hz, 1H ), 7.1 - 7.3(m, 10H).

13

C NMR (CDCl3):  31.2, 36.2,

42.5, 53.5, 126.5, 128.3, 129.3, 143.0. Anal Calcd for (C16H19N·HCl) C, 73.40; H, 7.70;
N, 5.35 Found: C, 72.30; H, 7.51; N, 5.24.

N-Methyl-4,4-diphenylbutan-1-amine oxalate (17). BH3•THF complex (1.0 M in THF,
0.335 g, 3.9 mmol) was added in a dropwise manner to a stirred solution of 75 (0.2 g,
0.78 mmol) in anhydrous THF (4 mL) under N2 at 0 °C. The mixture was slowly
warmed to rt and heated at reflux (6 h). The reaction mixture was allowed to cool to rt,
and HCl (6.0 M, 3 mL) was added with caution. The mixture heated at reflux (1 h) and
allowed to cool to rt, and the solvent was removed under reduced pressure. Water was
added and the residue was extracted with ether (25 mL). The aqueous portion was made
basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The organic layer was
washed with water and brine, dried (MgSO4), and concentrated under reduced pressure to
give 17 as an oil. It was then purified by medium pressure column chromatography,
CH2Cl2/MeOH (9:1) (0.148 g, 80%). Oxalate salt: mp 163 - 165 °C. (lit247 mp 162 - 164
o

C. 1H NMR (CDCl3): 1.49 (q, J = 7.8 Hz, 2H), 2.1 (q, J = 8.1 Hz, 2H ), 2.4 (s, 3H), 2.61

(t, J = 7.5 Hz, 2H) 3.9 (t, J = 7.5 Hz, 1H), 7.1 - 7.31 (m, 10H).
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13

C NMR (CDCl3): 

27.2, 36.2, 36.8, 50.8, 51.1, 126.2, 128.2, 129.3, 143.0. Anal Calcd for (C17H21N·
C2H2O4) C, 69.28; H, 7.03; N, 4.25; Found: C, 69.02; H, 7.11; N, 4.26.

N,N-Dimethyl-4,4-diphenylbutan-1-amine oxalate (18).247 BH3•THF complex (1.0 M
in THF, 0.317 g, 3.7 mmol) was added in a dropwise manner to a stirred solution of 76
(0.2 g, 0.74 mmol) in anhydrous THF (4 mL) under N2 at 0 °C. The mixture was slowly
warmed to rt and heated at reflux (6 h). The reaction mixture was allowed to cool to rt,
and HCl (6.0 M, 3 mL) was added with caution. The mixture was heated at reflux (1 h)
and allowed to cool to rt, and the solvent was removed under reduce pressure. Water was
added and the residue was extracted with ether (25 mL). The aqueous portion was made
basic with 10% NaOH and extracted with CH2Cl2 (3 × 25 mL). The organic layer was
washed with water and brine, dried (MgSO4), and concentrated under reduced pressure to
give 18 as an oil. It was then purified by medium pressure column chromatography,
CH2Cl2/MeOH (9:1) (0.155 g, 83%). Oxalate salt. mp 149 - 151 °C. (lit247 mp 152 – 154
°C). 1H NMR (CDCl3): 1.54 (q, J = 7.5 Hz 2H), 2.1 (q, J = 7.8 Hz, 2H), 2.3 (s, 6H), 2.49
(t, J = 7.8 Hz, 2H), 3.9 (t, J = 7.5 Hz, 1H), 7.1-7.3 (m, 10H). 13C NMR (CDCl3):  24.7,
36.3, 44.8, 51.6, 59.3, 126.3, 128.2, 129.1, 143.1. Anal Calcd for (C18H23N·C2H2O4·0.25
H2O) C, 69.04; H, 7.38; N, 4.02 Found: C, 69.32, H, 7.20, N, 4.12.

N-((9,10-Dihydroanthracen-10-yl)methyl)-2-phenylethanamine hydrochloride (20).
BH3•THF complex (1.0 M in THF, 1.0 g 12.2 mmol) was added in a dropwise manner to
a stirred solution of 77 (0.8 g, 2.44 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.
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The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture
was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture
was heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under
reduce pressure. Water was added and the residue was extracted with ether (25 mL). The
aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25
mL). The combined CH2Cl2 extracts were washed with water and brine, dried (MgSO4),
and concentrated under reduced pressure to give the amine as an oil. It was then purified
by medium pressure column chromatography, CH2Cl2/MeOH (9:1) to yield 20 (0.57 g,
75%). HCl salt: mp 188 – 190 °C. 1H NMR (CDCl3): 2.4 (m, 2H), 2.93 (m, 2H), 3.07 (d,
J = 8.1 Hz, 2H), 3.95 (d J = 18.6 Hz, 1H), 4.09 (d, J = 18.6 Hz, 1H), 4.5 (t, J = 7.8 Hz,
1H), 7.1 - 7.4 (m, 13H). 13C NMR (CDCl3):  36.6, 40.3, 48.7, 50.5, 57.5, 126.2, 126.8,
127.7, 128.7, 138.2, 138.6, 139.7. Anal Calcd for (C23H23N·HCl·0.25 H2O) C, 77.94; H,
6.96; N, 3.95; Found: C, 78.19; H, 6.87; N, 4.0.

N-((9,10-Dihydroanthracen-10-yl)methyl)-3-phenylpropan-1-amine

oxalate

(21).

BH3•THF complex (1.0 M in THF, 0.25 g 2.92 mmol) was added in a dropwise manner
to a stirred solution of 78 (0.2 g, 0.58 mmol) in anhydrous THF (4 mL) under N2 at 0 °C.
The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction mixture
was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The mixture
heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed under
reduced pressure. Water was added and the residue was extracted with ether (25 mL).
The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3 × 25
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mL). The combined CH2Cl2 extracts were washed with water and brine, dried (MgSO4),
and concentrated under reduced pressure to give amine as an oil. It was then purified by
medium pressure column chromatography, CH2Cl2/MeOH (9:1) to yield 57 (0.15 g,
80%). Oxalate salt: mp 208 - 210 °C. 1H NMR (CDCl3): 1.94 (m, 2H), 2.63 (t, J = 7.5Hz,
2H), 2.9 (m, 2H), 3.1 (d, J = 8.1 Hz, 2H), 3.97 (d, J = 18.6 Hz, 4.1 (d, J = 18.6 Hz, 2H),
4.3 (t, J = 8.1 Hz, 2H), 7.1 - 7.4 (m, 13H). 13C NMR (CDCl3):  29.6, 30.3, 35.7, 40.5,
49.5, 49.2, 58.6, 126.1, 126.8, 128.1, 128.7, 128.9, 138.2, 138.6, 139.7. Anal Calcd
(C24H25N·HCl·0.25 H2O) C, 73.99; H, 6.59; N, 3.31 Found: C, 74.11; H, 6.49; N, 3.33.

N-((9,10-Dihydroanthracen-9-yl)methyl)-4-phenylbutan-1-amine

hydrochloride

(22). BH3•THF complex (1.0 M in THF, 0.6 g 7.0 mmol) was added in a dropwise
manner to a stirred solution of 79 (0.5 g, 1.4 mmol) in anhydrous THF (4 mL) under N2
at 0 °C. The mixture was slowly warmed to rt and heated at reflux (6 h). The reaction
mixture was allowed to cool to rt, and HCl (6.0 M, 3 mL) was added with caution. The
mixture heated at reflux (1 h) and allowed to cool to rt, and the solvent was removed
under reduced pressure. Water was added and the residue was extracted with ether (25
mL). The aqueous portion was made basic with 10% NaOH and extracted with CH2Cl2 (3
× 25 mL). The combined CH2Cl2 extracts were washed with water and brine, dried
(MgSO4), and concentrated under reduced pressure to give amine as an oil. It was then
purified by medium pressure column chromatography, CH2Cl2/MeOH, (9:1) to yield 22
(0.38 g, 80%). HCl salt: mp 198 - 200 °C. 1H NMR (CDCl3): 1.63 (m, 4H), 2.61 (m, 2H),
2.9 (m, 2H), 3.1 (m, 2H), 3.97 (d, J = 18.2 Hz, 1H), 4.1 (d, J = 18.2 Hz, 1H), 4.4 (t, J =
105

8.1 Hz, 2H), 7.1 - 7.4 (m, 13H). 13C NMR (CDCl3):  28.6, 30.1, 35.7, 40.4, 49.5, 50.2,
58.6, 126.0, 126.8, 128.1, 128.6, 128.7, 138.2, 138.6, 139.7. Anal Calcd for
(C25H27N·HCl·0.25 H2O) C, 77.59; H, 7.55; N, 3.61 Found: C, 77.75; H, 7.56; N, 3.62.

[(9,10-Dihydro-9-anthryl)methyl]trimethyl ammonium iodide (23).248 To a solution
of compound 3 (0.2 g, 0.79 mmol) in anhydrous CH2Cl2 (4 mL) was added iodomethane
(0.168 g, 3.95 mmol). The reaction mixture was stirred at rt for 3 h. Ethyl acetate (3 mL)
was then added to the mixture in a dropwise manner resulting in the formation of white
turbid solution. The reaction mixture was then cooled, refrigerated to obtain a white solid.
The solid was then purified by medium pressure column chromatography, CH2Cl2/MeOH
(10:1) to obtain 23 (0.22 g, 70%). mp 148 - 150 °C. 1H NMR (DMSO): 3.04 (s, 9H), 3.54
(d, J = 7.2 Hz, 2H), 4.79 (t, J = 7.2 Hz), 3.97 (d, J = 18.3 Hz, 1H), 4.01 (d, J = 18.3 Hz,
1H), 4.28 (m, 8H).

C NMR (DMSO):  35.5, 42.6, 53.5, 68.5, 127.2, 127.9, 138.1,

13

138.6. Anal Calcd for (C18H22N) C, 56.33; H, 5.90; N, 3.64 Found: C, 56.15, H, 5.87; N,
3.63.

(7,12-Dihydrotetraphen-12-yl)methanamine fumarate (24). Methanesulfonic acid (20
ml) was added to compound 84 (0.5 g, 1.8 mmol) and was stirred for 1 h. The reaction
mixture was allowed to cool and then added to a cold solution of 10% NaOH until basic.
The mixture was then extracted with CH2Cl2 (75 ml). Combined extracts were washed
with brine, water, and dried (MgSO4). Evaporation of solvent gave a mixture of 24
(major) and 25 (minor) as the products. Further purification was carried out by medium
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pressure column chromatography, CH2Cl2/MeOH (10:1) to obtain product as a light
brown oil (0.040 g, 20%). However, the final mixture obtained was mixture of 24 and 25.
Fumarate salt: mp 148 – 150 °C. 1H NMR (CDCl3): 3.1 (m, 1H), 3.18 (m, 1H), 4.1 (d, J =
18.6 Hz, 2H), 4.21 (d, J = 18.6 Hz, 2H), 4.6 (t, J = 7.2 Hz), 7.2 - 8.1 (m, 9H); 13C NMR
(CDCl3):  37.2, 44.1, 47.84, 105.3, 117.8, 125.2, 134.7, 157.1. Anal.Calcd
(C19H17NO·C4H6O4) C, 73.58; H, 5.63; N, 3.73.

(7,12-Dihydro-3-methoxytetraphen-12-yl)methanamine fumarate (26).
Methanesulfonic acid (20 ml) was added to the compound 85 (0.5 g, 1.62 mmol) and was
stirred for 1 h. The reaction mixture was allowed to cool and then added to a cold
solution of 10% NaOH until basic, and extracted with CH2Cl2 (75 ml). Combined
extracts were washed with brine, water, and dried (MgSO4). Evaporation of solvent gave
a mixture of 26 (major) and 27 (minor) as the products. Further purification was carried
out by medium pressure column chromatography, CH2Cl2/MeOH (10:1). Only the major
product was separated (0.040 g, 26%) as light brown oil. Fumarate salt: mp 132 – 135 °C.
1

H NMR (CDCl3): 2.97 (m, 1H,) 3.05 (m, 1H) 3.94 (s, 3H), 3.98 (d, J = 18.6 Hz, 2H),

4.24 (d, J = 18.6 Hz, 2H), 4.75 (t, J = 7.2 Hz), 7.17 - 8.1 (m, 9H); 13C NMR (CDCl3): 
35.99, 45.9, 47.84, 55.53, 106.3, 118.8, 125.6, 134.7, 156.4. Anal. Calcd for
(C20H19NO·C4H6O4·0.5 H2O) C, 68.0; H, 5.95; N, 3.30 Found: C, 67.49, H, 5.54; N, 3.52.
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4-(4-(Dimethylamino)-1-phenylbutyl)benzoic acid (29).249 Compound 89 (0.4 g, 1.35
mmol) was dissolved in a solution of MeOH:CH2Cl2 (5:1) (10 mL). Pd/C (0.2 g 10%)
was added and the mixture was stirred overnight under a hydrogen atmosphere. The
reaction mixture was filtered with celite and the filtrate was concentrated under reduced
pressure. The residue was triturated with diethyl ether and the precipitate was collected
by filtration to obtain product. Recrystallization from ethanol and petroleum ether
afforded 29 as a faint yellow powder (0.38 g, 95%). mp 233 – 235 °C. 1H NMR (DMSO):
1.56 (m, 2H), 2.13 (m, 2H), 2.6 (s, 6H), 3.05 (t, J = 7.2 Hz, 2H), 4.07 (t, J = 7.2 Hz, 1H),
7.22 -7.88 (m, 9H);

13

C NMR (DMSO):  23.07, 32.11, 42.6, 50.9, 56.8, 127.0, 128.4,

129.6, 144.7, 150.4, 167.89. Anal Cacld for (C19H23NO2·HCl·H2O) C, 64.85; H, 7.44; N,
3.98 Found: C, 64.18; H, 7.08; N, 3.70. (ESIMS (-ve) calcd for C19H23NO2 [(M-H)-]
298.17 Found 298.22.

6,11-Dihydro-11-oxo-dibenz[b,e]oxepin-2-acetic acid (31).237 A mixture of compound
93 (1.43 g, 5.0 mmol), polyphosphoric acid (9.0 g) and 7 mL of acetic acid was stirred at
80 °C for 6 h. After hydrolyzing the mixture with 75 mL of water, 10% NaOH was added
until basic and the aqueous mixture was extracted with ether. Acidification of the icecooled aqueous phase with concentrated HCl provided a solid which was purified by
medium pressure column chromatography, CH2Cl2/MeOH (10:1) to obtain 31 (0.53 g,
40%). mp 134 - 136 °C. (lit237 135 - 136 °C).
2H), 7.0 - 8.1 (m, 7H);

13

1

H NMR(CDCl3): 3.70 (s, 2H), 5.21 (s,

C NMR(CDCl3):  39.48, 73.19, 120.74, 124.69, 126.65,

127.39, 128.86, 129.07, 132.17, 132.38, 135.04, 135.98, 139.96, 160.16, 176.77, 190.45;
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Anal Calcd for (C16H12O4) C, 71.63; H, 4.50; O, 23.85 Found: C, 71.18; H, 4.46; O,
23.58.

6,11-Dihydrodibenz[b,e]oxepin-2-acetic acid (32).237 To a stirred solution of compound
31 (0.1 g, 0.37 mmol) in acetic acid (3 mL) was added Zn powder (0.3 g, 4.46 mmol) and
the mixture was refluxed for 2 h, cooled and filtered. The filtrate was concentrated in
vacuum to obtain syrupy residue. After addition of water to the syrupy residue, the
mixture was extracted with CHCl3 (3 × 25 mL) which was washed with water, dried
(MgSO4) and concentrated. The residue obtained was purified by crystallization from
benzene to yield product 32 (0.055 g 60%). mp 156 - 158 °C. (lit237 155 – 157 °C). 1H
NMR(CDCl3): 3.57 (s, 2H), 4.24 (s, 2H), 5.32 (s, 2H), 6.8 - 7.3 (m, 7H);

13

C

NMR(CDCl3):  38.47, 39.69, 70.27, 119.68, 125.27, 125.40, 125.64, 126.65, 127.58,
127.65, 127.81, 128.20, 128.28, 128.46, 128.63, 131.32, 135.26, 139.32, 155.74, 179.21.
Anal. (C16H14O3·0.75 H2O) C, 71.76; H, 5.83 Found: C, 71.87; H, 5.45.

11-Methylene-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid (33). To a solution of
compound 94 (0.1 g) in absolute ethanol was added 10% NaOH and refluxed for 3 h.
The reaction mixture was then cooled and concentrated. HCl was added to the mixture
and extracted with CH2Cl2 (3 × 25 mL). The solvent was concentrated in vacuum to
obtain the product 33 as a pale white solid (0.085 g, 90%). mp 162 - 164 °C. 1H
NMR(CDCl3): 3.62 ( s, 2H), 5.2 ( s, 2H), 5.32 (s, 1H), 5.74 (s, 1H), 6.86 (d, J = 8.4 Hz
1H), 7.14 (d, J = 8.4 Hz 1H), 7.33 - 7.38 (m, 4H);
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C NMR(CDCl3):  39.72, 70.39,

13

117.20, 119.62, 125.41, 126.48, 127.11, 127.71, 128.73, 130.14, 130.65, 133.69, 143.36,
147.53, 154.85, 177.62. Anal Calcd for (C17H14O3·H2O) C, 69.61; H, 5.84 Found: C,
69.87; H 5.84. ESIMS (-ve) m/z calcd for C17H13O3 [(M-H)-] 265.09, Found 264.963.

(E,Z)-(11-[4-Methylpentylidene]-6,11-dihydrobenz[b,e]oxepin-2-acetic acid (34). In a
two-necked round-bottomed flask equipped with a stirrer was added compound 101 (0.1
g, 0.31 mmol), acetonitrile (4 mL), TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy free
radical (0.0339 g, 0.0217 mmol), sodium chlorite (0.056 g, 0.62 mmol) and 0.67 M
sodium phosphate buffer (1.2 mL) and kept for stirring. A dilute bleach solution (0.15
mL) was added to this mixture in a dropwise manner. The resultant mixture was heated to
35 °C and stirring was continued until reaction was completed (6 h). After cooling the
reaction mixture to 25 °C, water (5 mL) was added and the pH was adjusted to 8.0 by
addition of 2N NaOH. The reaction mixture was than poured into ice-cold sodium sulfite
solution (30 mL) maintained below 20 °C. After stirring for 30 min at rt, methyl t-butyl
ether (MTBE) was added and the rapidly stirred mixture was acidified with 2 N HCl to
pH 3-4. The organic layer was separated and washed with water, brine, dried (MgSO4)
and concentrated to give 34 as a mixture of geometrical isomers (E/Z = 3/7) as an oil
(0.041 g, 40%). 1H NMR(CDCl3): 0.91 (d, J = 6.6 Hz, 6H), 1.40 (q, J = 7.2 Hz, 2H), 1.62
(m, 1H), 2.42 (q, J = 7.2 Hz, 2H), 3.58 (s, 2H), 5.71 (t, J = 7.8 Hz, 1H), 6.1 (t, J = 7.8 Hz,
1H), 6.8 - 7.3 (m, 7H);

C NMR(CDCl3):  22.07, 27.06, 27.29, 38.63, 39.68, 69.95,

13

119.31, 123.60, 124.43, 125.86, 126.92, 127.04, 128.68, 129.42, 131.91, 133.21, 133.54,
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137.84, 145.44, 154.28, 177.43; Anal Calcd for (C22H24O3) C, 78.54, H, 7.19 Found: C,
78.1; H, 9.7. ESIMS (-ve) calcd for C22H24O3 [(M-H)-] 335.16, found 335.23.

6,11-Dihydro-11-oxo-dibenz[b,e]oxepin-2-acetic acid ethyl ester (35).237 A mixture of
compound 31 (1.0 g), absolute ethanol (10 mL) and concentrated sulfuric acid (2 mL)
was refluxed for 6 h. The solution was then cooled and concentrated. The crude product
obtained was dissolved in ether, washed with 5% NaOH solution, water and dried
(MgSO4) to yield solid. The solid was purified by medium pressure column
chromatography, CH2Cl2/MeOH (9:1) to obtain 35 (0.99 g, 90%). mp 90 - 92 °C. (lit237
89 – 91 °C). 1H NMR(CDCl3): 1.26 (t, J = 7.2 Hz, 3H), 3.60 (s, 2H), 4.14 (q, J = 7.2 Hz,
2H), 5.17 (s, 2H), 7.0 - 7.57 (m, 7H);
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C NMR(CDCl3):  14.44, 40.48, 61.22, 73.84,

121.26, 125.33, 128.04, 128.17, 129.49, 129.70, 132.65, 133.0, 135.77, 136.60, 140.69,
160.67, 171.69, 191.11.

11-Oxo-2-[4,4-dimethyl-2-oxazolin-2-yl)methyl]-6,11-dihydrobenz[b,e]oxepin

(36).

To a solution of compound 31 (0.3 g, 1.18 mmol) in CH2Cl2 (8 mL) and pyridine (1 mL)
was added SOCl2 (0.214 g, 1.8 mmol) at 0 °C, and the mixture was stirred at rt for 2 h.
The reaction mixture was concentrated and the residue obtained was treated with 2amino-2-methylpropanol (0.77 g, 8.73 mmol) in toluene (5 mL) at 50 °C for 3 h. The
reaction mixture was then diluted with EtOAc, washed with brine, dried (MgSO4) and
concentrated. The residue obtained was recrystallized from toluene to obtain
carboxamide (0.2 g, 0.58 mmol) which was suspended in CH2Cl2 (8 mL). To this
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suspension was added SOCl2 (0.082 g 0.69 mmol) at 0 °C, and the mixture was stirred at
rt for 1 h. The reaction mixture was diluted with CH2Cl2, washed with brine, dried
(MgSO4) and concentrated to obtain product which was purified by medium pressure
column chromatography, hexane/EtOAc (2:1) to yield 36 as an oil (0.05g, <5%).

1

H

NMR(CDCl3): 1.31 (s, 6H), 3.63 (s, 2H), 3.95 (s, 2H), 5,21 (s, 2H), 7.0 - 8.1 (m, 7H); 13C
NMR(CDCl3):  27.94, 33.51, 66.72, 73.17, 78.94, 120.67, 124.72, 127.34, 128.63,
128.81, 129.04, 131.55, 132.29, 135.09, 135.30, 140.06, 157.81, 159.91, 163.57, 175.87,
186.23, 190.42.

(E,Z)-(11-[4-Methylpentylidene]-6,11-dihydrobenz[b,e]oxepin-2-acetic acid methyl
ester (37). To a suspension of 4-(methylpentane) triphenylphosphonium bromide (0.79 g,
1.86 mmol) in anhydrous THF (5 mL) under N2 atmosphere at 0 °C was added a 2.5 M
solution of n-BuLi (0.35 g, 5.58 mmol) in hexane. The solution was stirred under the
same condition for 1 h. A solution of 31 (0.1 g, 0.37 mmol) in THF (2 mL) was added
and the resulting mixture was stirred at rt for 2 h. After being concentrated, the reaction
mixture was diluted with water, washed with ether, and than neutralized. The resulting
solution was concentrated and the residue obtained was dissolved in methanol (10 mL)
containing p-TsOH·H2O (0.1 g, 0.55 mmol) and refluxed for 2 h. The reaction mixture
was concentrated, diluted with EtOAc (50 mL) and washed with water. The organic layer
was dried (MgSO4) and concentrated in vacuum to obtain product which was purified by
medium pressure column chromatography, CH2Cl2/MeOH (9:1) to yield 37 as an oil. The
product obtained was in very low yield (<5%). 1H NMR(CDCl3): 0.91 (d, 6H), 1.28 (m,
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2H), 1.65 (m, 2H), 2.44 (m, 1H), 3.5 (s, 2H), 3.71 (s, 3H), 5.17 (bs, 2H), 5.67 (t, J = 7.5
Hz, 1H), 6.0 (t, J = 7.5 Hz 1H), 6.7 - 7.3 (m, 7H).

9,10-Dihydroanthracene-10-carboxylic acid (43). To a well-stirred suspension of 9,10dihydroanthracene 42 (4.5 g, 25.0 mmol) in anhydrous ether (40 mL) was added n-BuLi
(1.6 g, 25 mmol) under N2 at 0 °C. The resulting dark solution was stirred at rt for 2 h and
then heated to reflux for 45 min. The reaction mixture was then poured over an excess of
dry ice slurry, extracted with water and acidified with HCl. The precipitate obtained was
collected by vacuum filtration and recrystallized from 2-propanol to yield 43 (2.5 g, 45%)
as white solid. mp 200 - 202 °C. (lit243 200 - 207 °C). 1H NMR (CDCl3): 3.9 (s, 1H), 4.2
(s, 1H), 4.9 (s, 1H), 7.26 (s, 4H), 7.42 (s, 4H).

2-(9,10-Dihydroanthracen-10-yl)-N-methylacetamide (44). Thionyl chloride (2.65 g,
22.2 mmol) was added under N2 to a stirred solution of compound 43 (l.0 g, 4.45 mmol)
in anhydrous benzene (4 mL). The solution was heated at reflux (2 h), allowed to cool
and the excess benzene and thionyl chloride were removed under reduced pressure to
provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an
ice bath (0 °C). Methylamine/THF (2 M, 0.276 g, 8.9 mmol) solution was added
dropwise into the stirred solution, and the mixture was stirred at rt (2 h). The solvent was
removed under reduced pressure to give a white solid. Water (20 mL) was added, and the
suspension was extracted with EtOAc (3 × 25 mL). The combined extracts were washed
with water, brine and dried (MgSO4). Removal of solvent under reduced pressure gave
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crude amide as viscous oil. The resulting amide was purified using medium pressure
chromatography, petroleum ether/EtOAc (6:4) to yield 44 (0.756 g, 72%). 1H NMR
(CDCl3): 2.65 (s, 3H), 3.95 (d, J = 18.3 Hz, 1H), 4.12 (d, J = 18.3 Hz, 1H), 4.85 (s, 1H),
7.25 - 7.46 (m, 8H).

2-(9,10-Dihydroanthracen-10-yl)-N,N-dimethylacetamide (45).243 Thionyl chloride
(2.65 g, 22.3 mmol) was added under N2 to a stirred solution of compound 43 (1.0 g, 4.45
mmol) in anhydrous benzene (4 mL). The solution was heated at reflux (2 h), allowed to
cool and the excess benzene and thionyl chloride were removed under reduced pressure
to provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in
an ice bath (0 °C). Dimethylmethylamine/THF (2 M, 0.4 g, 8.9 mmol) solution was
added dropwise into the stirred solution, and the mixture was stirred at rt (2 h). The
solvent was removed under reduced pressure to give a white solid. Water (20 mL) was
added, and the suspension was extracted with EtOAc (3 × 25 mL). The combined extracts
were washed with water, brine and dried (MgSO4). Removal of solvent under reduced
pressure gave crude amide as oil. The resulting oil was purified using medium pressure
chromatography, petroleum ether/EtOAc (6:4) to yield 45 (0.83 g, 75%). 1H NMR
(CDCl3): 3.06 (s, 6H), 4.0 (d, J = 18.6 Hz, 1H), 4.51 (d, J = 18.6 Hz, 1H), 5.34 (s, 1H),
7.20 - 7.37 (m, 8H).

9-(2-Nitrovinyl)anthracene (47).191 Ammonium acetate (0.56 g, 7.27 mmol) was added
to a well stirred solution of nitromethane (30 mL) and 9-anthraldehyde 46 (1.5 g, 7.27
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mmol). The reaction mixture was heated to reflux for 40 min. The red solution obtained
was evaporated under reduced pressure to remove nitromethane. The oily red solid was
then dissolved in EtOAc and washed with water and brine. The EtOAc was removed
under reduced pressure to yield nitrostyrene product 47 (95%). 1H NMR (CDCl3): 7.5 7.6 (m, 4H), 7.68 (s, 1H), 7.7 - 7.8 (m, 4H), 7.78 (d, J = 14 Hz, 1H) 7.9 (d, J = 14 Hz,
1H).

2-(Anthracen-9-yl)ethanamine (48). Compound 47 (0.5 g, 2.2 mmol) was added to an
ice-cold solution of THF (25 mL) and LiAlH4 (0.22 g, 6.0 mmol). The reaction was
heated to reflux for 5 h and then cooled. To this was added 1 ml water and 1 mL 10%
NaOH. Celite was then added to the mixture and filtered. The mixture was washed with
CH2Cl2. The filtrate was washed with water, dried (MgSO4), and the solvent was
removed under reduced pressure to yield crude product as oil that was purified by
medium pressure column chromatography, CH2Cl2/MeOH (9:1) to obtain 48 (0.3 g,
80%). 1H NMR (CDCl3): 2.8 (t, J = 7.8 Hz, 2H), 3.0 (t, J = 7.8 Hz, 2H), 7.4 - 7.5 (m,
4H), 7.56 (s, 1H), 7.6 - 7.7(m, 4H).

9-Bromomethylanthracene (50).193 A suspension of 9-hydroxymethylanthracene (49,
1.5 g, 7.2 mmol) in toluene (40 mL) was cooled to 0 oC followed by addition of
phosphorus tribromide (0.8 mL, 8.4 mmol) via syringe. The mixture was stirred at 0 °C
for 1 h and then warmed to rt, during which the reaction became homogeneous. Saturated
Na2CO3 solution (15 mL) was added slowly and the reaction was stirred until it cooled to
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rt. The phases were separated, and the organic phase was washed with water (10 mL),
brine (10 mL) and dried over MgSO4. The yellow filtrate was concentrated to minimum
volume, and then stored at 0 °C for crystallization. The yellow needle-like solid was
collected and dried in vacuum (1.24 g). The mother liquid was concentrated and purified
using medium pressure column chromatography (0.6 g). The two parts were combined to
give the product 50 (total 1.84 g, 94%) as yellow needles. mp 145 -148 °C. 1H NMR
(CDCl3): 5.5 (s, 2H), 7.2 - 8.4 (m, 9H).

2-(Anthracen-9-yl)acetonitrile (51). A solution of compound 50 (1.5 g, 5.53 mmol) in
DMSO (15 mL) was added over 10 min to a rapidly stirred suspension of KCN (0.54 g,
8.29 mmol) in DMSO (30 mL) at 70 °C under N2. The mixture was stirred for an
additional 40 min, cooled to rt and then diluted with water. The aqueous layer was
saturated with sodium chloride and then extracted with ether (3 × 25 mL). The combined
extracts were washed with water, dried (MgSO4,), filtered, and concentrated to yield
product 51 (0.96 g, 80%) as a pale white solid. mp 154 - 156 °C. 1H NMR (CDCl3): 4.61
(s, 2H), 7.2 - 8.5 (m, 9H).

2-(Anthracen-9-yl)acetic acid (52). To a suspension of compound 51 (0.95 g, 4.37
mmol) in ethylene glycol (50 mL) was added KOH (0.97 g, 17.48 mmol) in 10 ml of
water. The mixture was heated to reflux for 24 h until the entire solid was completely
dissolved. The hot solution was filtered, and the filtrate was acidified with dilute HCl to
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obtain precipitate of product 52 (1.08 g, 100%). mp 212 - 214 °C. (lit244 208 - 212 oC). 1H
NMR (CDCl3): 4.63 (s, 2H), 7.4 - 8.5 (m, 9H).

2-(9,10-Dihydroanthracen-9-yl)acetic acid (53). To a refluxing solution of compound
52 (0.375 g, 1.58 mmol) in 1-pentanol (10 mL) were added sodium pieces (0.36 g, 10
equiv) slowly. The reaction mixture was stirred for 10 min until all the sodium dissolved.
Water (10 mL) was added to the cooled mixture and then made acidic with 5% HCl. The
reaction mixture was dried under high vacuum and the oily solution obtained was
extracted with chloroform, dried (MgSO4) and concentrated to yield pure product 53 (0.3
g, 80%) as white solid. mp 168 - 170 °C. (lit245 167 - 169 °C) 1H NMR (CDCl3): 2.63 (s,
2H), 4.48 (t, J = 6.9 Hz, 1H), 3.91 (d, J = 18.6 Hz, 1H) 4.06 (d, J = 18.6 Hz, 1H), 7.4 8.4 (m, 9H).

2-(9,10-Dihydroanthracen-9-yl)-N-methylacetamide (54). Thionyl chloride (0.86 g,
7.3 mmol) was added under N2 to a stirred solution of compound 53 (0.35 g, 1.45 mmol)
in anhydrous benzene (4 mL). The solution was heated at reflux (2 h), allowed to cool
and the excess benzene and thionyl chloride were removed under reduced pressure to
provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an
ice bath (0 °C). Methylamine/THF (2 M, 0.09 g, 2.9 mmol) solution was added dropwise
into the stirred solution, and the mixture was stirred at rt (2 h). The solvent was removed
under reduced pressure to give a white solid. Water (20 mL) was added, and the
suspension was extracted with EtOAc (3 × 25 mL). The combined extracts were washed
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with water, brine and dried (MgSO4). Removal of solvent under reduced pressure gave
the crude amide as yellow oil. The resulting amide was purified using medium pressure
chromatography, CH2Cl2/Acetone to yield 54 (0.27g, 76%). 1H NMR (CDCl3): 2.16 (s,
3H), 2.41 (d, J = 7.5 Hz, 2H), 3.93 (d, J = 18.3 Hz, 1H), 4.05 (d, J = 18.3 Hz, 1H), 4.56
(t, J = 7.5 Hz, 1H), 7.1 -7.3 (m, 8H).

2,(9,10-Dihydroanthracene-9-yl)ethanol (56). Na2K silica gel (2 g) was added to a well
stirred solution of 2-(anthracen-9-yl)ethanol 55 (0.75 g, 4.4 mmol) in anhydrous THF (10
mL) under N2 at rt. The reaction mixture was refluxed for 15 min then allowed to cool to
rt and quenched with water (50 mL). The solid precipitate obtained was filtered and
washed with EtOAc (3 × 25 mL). The filtrate was collected and the mixture was
extracted. The EtOAc portion was dried (MgSO4) and concentrated under reduced
pressure to obtain viscous yellow oil. This was purified using medium pressure column
chromatography, CH2Cl2/MeOH (9:1) to give 56 (0.65 g, 86%). 1H NMR (CDCl3): 1.76
(q, J = 6.3 Hz, 2H), 3.49 (t, J = 6.3 Hz, 2H), 3.93 (d, J = 18.2 Hz, 1H), 4.15 (d, J = 18.2
Hz, 1H), 4.08 (t, J = 7.2 Hz, 1H), 7.1 - 8.3 (m, 8H).

C NMR (CDCl3):  31.5, 35.4,
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38.5, 42.3, 60.1, 62.3, 130.1, 131.2, 136.2, 140.2.

2-(9,10-Dihydroanthracene-9-yl)acetaldehyde (57). A solution of compound 56 (0.50
g, 2.2 mmol) in anhydrous CH2Cl2 (10 mL) was added to a stirred mixture of Dess-Martin
(periodinane) oxidant (1.39 g, 3.3 mmol) in CH2Cl2. The reaction mixture was stirred for
1h then diluted with ether (50 mL) and poured into 1.3 M NaOH (50 mL). The ether layer
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was separated and extracted with 1.3 M NaOH (3 × 15 mL). The ether portion was
washed with water (2 × 20 mL), brine (20 mL), dried (MgSO4) and concentrated under
reduced pressure to yield product as oil. The resulting oil was purified by medium
pressure column chromatography, Petroleum ether/EtOAc (9:1) to give 57 (0.391 g, 80%)
as an oil. 1H NMR (CDCl3): 2.76 (d, J = 7.5 Hz, 2H), 3.86 (d, J = 18.3 Hz, 1H), 4.05 (d, J
= 18.3 Hz, 1H), 4.59 (t, J = 6.9 Hz, 1H), 7.0 - 7.2 (m, 8H), 9.7 (s, 1H).

13

C NMR

(CDCl3): 34.85, 40.77, 50.0, 126.19, 127.35, 137.21, 138.5, 200.0.

3-(Anthracen-9-yl)propanoic acid (61).197 Anthrone 58 (3.0 g, 15.5 mmol) was added
to a well stirred solution of potassium t-butoxide (2.17 g, 19.38 mmol) dissolved in
anhydrous t-butyl alcohol (30 mL). The solution was stirred for 1h at rt. Acrylonitrile (0.9
g, 17.05 mmol) dissolved in 10 mL of anhydrous t-butyl alcohol was added dropwise
over a period of 1 h to this reddish-brown solution of potassium anthranolate. During the
addition of the nitrile a bright red precipitate separated. The reaction mixture was
refluxed for 2 h and a clear deep red-colored solution was obtained. 5% HCl (2 mL) was
added to the cooled mixture and t-butyl alcohol was removed under vacuum to yield a
brown solid. Concentrated HCl (20 mL) was added to the residue which was refluxed for
12 h. After cooling, HCl was removed with the aid of a sintered glass filter and the solid
remaining in the flask was washed with water. The solid acid was dissolved in a mixture
of concentrated ammonium hydroxide (50 mL) and water (30 mL) and the resulting
solution was heated at 90 °C for 4 h with 9.5 g of zinc dust. The cooled reaction mixture
was filtered to remove excess zinc and the filtrate was extracted with ether. The aqueous
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layer was acidified with HCl to yield a crude acid which was filtered and dried.
Recrystallization of the crude acid with 2-propanol gave 61 (1.96 g, 51% yield) as pale
yellow crystals. mp 194 - 195 °C. (lit197 194 – 195 °C). 1H NMR (CDCl3): 2.85 (t, J = 6.9
Hz, 2H), 4.01 (t, J = 6.9 Hz, 2H), 7.4 - 8.3 (m, 9H).

3-(9,10-Dihydroanthracen-9-yl)propanoic acid (62).197 To a refluxing solution of
compound 61 (0.5 g, 2.0 mmol) in 1-pentanol (15 mL) was added sodium pieces (0.46 g,
20 mmol) slowly. The reaction mixture was then stirred for 10 min until all the sodium
dissolved. The reaction mixture was cooled, water (10 mL) was added to the mixture and
made acidic with 5% HCl. The reaction mixture was dried under high vacuum and the
oily solution obtained was extracted with chloroform, dried (MgSO4,) and concentrated
to give crude product. The crude product obtained was purified by medium pressure
chromatography, CH2Cl2/MeOH (9:1) to give 62 (0.4 g, 85%) as a white solid. mp 138 140 °C. (lit197 137 - 140 °C). 1H NMR (CDCl3): 1.96 (q, J = 6.9 Hz, 2H), 2.32 (t, J = 7.2
Hz, 2H), 3.95 (t, J = 7.2 Hz, 1H), 3.9 (d, J = 18.6 Hz, 1H), 4.0 9 (d, J = 18.6 Hz, 1H), 7.1
- 7.29 (m, 8H).

3-(9,10-Dihydroanthracen-9-yl)propanamide (63). Thionyl chloride (0.14 g, 1.18
mmol) was added under N2 to a stirred solution of compound 62 (0.15 g, 0.59 mmol) in
anhydrous benzene (4 mL). The solution was heated at reflux (2 h), allowed to cool and
the excess benzene and thionyl chloride were removed under reduced pressure to provide
an oil. The brown oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an
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ice bath (0 °C). Anhydrous ammonia was slowly bubbled into the stirred solution for 0.5
h, and the mixture was stirred at rt (2 h). The solvent was removed under reduced
pressure to give oil. Water (20 mL) was added, and the suspension was extracted with
EtOAc (3 × 25 mL). The combined extracts were washed with water and brine and dried
(MgSO4). Removal of solvent under reduced pressure gave the crude amide. The
resulting amide was purified using medium pressure chromatography, CH2Cl2/Acetone
(9:1) to yield 63 (0.11 g, 75%). mp 131 - 133 °C. 1H NMR (CDCl3): 1.96 (t, J = 7.2 Hz,
2H), 2.18 (q, J = 7.2 Hz, 2H), 3.97 (t, J = 7.5 Hz, 1H), 3.90 (d, J = 18.2 Hz, 1H), 4.08 (d,
J = 18.2 Hz, 1H), 7.2 - 8.3 (m, 8H).

3-(9,10-Dihydroanthracen-10-yl)-N-methylpropanamide (64). Thionyl chloride (0.14
g, 1.18 mmol) was added under N2 to a stirred solution of compound 62 (0.15 g, 0.59
mmol) in anhydrous benzene (4 mL). The solution was heated at reflux (2 h), allowed to
cool and the excess benzene and thionyl chloride were removed under reduced pressure
to provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in
an ice bath (0 °C). Methylamine/THF (2 M, 0.036 g, 1.18 mmol) solution was added
dropwise into the stirred solution, and the mixture was stirred at rt (2 h). The solvent was
removed under reduced pressure to give a white solid. Water (20 mL) was added, and the
suspension was extracted with EtOAc (3 × 25 mL). The combined extracts were washed
with water, brine and dried (MgSO4). Removal of solvent under reduced pressure gave
crude amide. The resulting amide was purified using medium pressure chromatography,
CH2Cl2/Acetone (9:1) to yield 64 (0.12 g, 78%). mp 148 - 150 °C. 1H NMR (CDCl3):
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1.94 (t, J = 8.1 Hz, 2H), 2.12 (q, J = 7.2Hz, 2H), 2.73 (d, J = 4.8Hz, 3H), 3.95 (t, J =
7.5Hz, 1H), 3.89 (d, 18.6 Hz, 1H), 4.07 (d, J = 18.6 Hz, 1H), 7.1 - 7.3 (m, 8H). 13C NMR
(CDCl3):  25.8, 32.5, 33.7, 34.7, 46.0, 125.8, 127.5, 135.6, 139.2, 172.6.

3-(9,10-Dihydroanthracen-10-yl)-N,N-dimethylpropanamide (65). Thionyl chloride
(0.14 g, 1.18 mmol) was added under N2 to a stirred solution of compound 62 (0.15 g,
0.59 mmol) in anhydrous benzene (4 mL). The solution was heated at reflux (2 h),
allowed to cool and the excess benzene and thionyl chloride were removed under reduced
pressure to provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and
cooled in an ice bath (0 °C). Dimethylmethylamine/THF (2 M, 0.053 g, 1.18 mmol)
solution was added dropwise into the stirred solution, and the mixture was stirred at rt (2
h). The solvent was removed under reduced pressure to give a white solid. Water (20 mL)
was added, and the suspension was extracted with EtOAc (3 × 25 mL). The combined
extracts were washed with water, brine and dried (MgSO4). Removal of solvent under
reduced pressure gave the crude amide. The resulting amide was purified using medium
pressure chromatography, CH2Cl2/Acetone (9:1) to yield 65 (0.124 g, 76%) as an oil. 1H
NMR (CDCl3): 1.98 (t, J = 7.5 Hz, 2H), 2.26 (m, 2H), 2.87 (s, 3H), 2.92 (s, 3H), 4.04 (t,
J = 7.2 Hz, 1H), 3.85 (t, J = 18.6 Hz, 1H), 4.11 (d, 18.6 Hz, 1H), 7.20 - 7.29 (m, 8H). 13C
NMR (CDCl3):  25.5, 33.5, 32.2, 34.8, 45.7, 125.7, 127.4, 135.6, 139.5, 172.0.

3,3-Diphenylpropanal (68). A solution of 3,3-diphenylpropanol 67 (1.5 g, 7.0 mmol) in
anhydrous CH2Cl2 (15 mL) was added to a stirred mixture of Dess-Martin (periodinane)
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oxidant (3.2 g, 7.7 mmol) in CH2Cl2 (30 mL). After 50 min, the reaction mixture was
diluted with ether (50 mL) and poured into 1.3 M aqueous NaOH (50 mL). The ether
layer was separated and extracted with 1.3 M NaOH (30 mL). The ether layer was
washed with water, dried (MgSO4), and the solvent was removed under reduced pressure
to give the 68 (1.11 g, 75%) as an oil. 1H NMR (CDCl3): 3.1 (m, 2H), 4.2 (t, J = 7.5 Hz,
1H), 7.1 - 7.3 (m, 10H), 9.2 (s, 1H). 13C NMR (CDCl3):  52.2, 55.8, 126.3, 128.2, 129.3,
143.1, 202.0.

4,4-Diphenylbutyronitrile (71). To a suspension of potassium metal (0.69 g, 17.76
mmol) and catalytic amount of ferric nitrate in liquid ammonia (50 mL, -70 °C) was
added diphenylmethane 69 (2.5 g, 14.8 mmol) dissolved in ether (15 mL) over 15 min.
The deep red suspension obtained was stirred for 30 min. To this reaction mixture was
added bromopropionitrile 70 (1.98 g, 14.8 mmol) in ether. After the disappearance of
deep red color, NH3 was allowed to evaporate. The organic layer was separated and
residue was extracted twice with ether (40 mL). The combined ether extracts were
washed with 0.1 N HCl (2 × 30 mL) water (50 mL), brine (50 mL) and dried (MgSO 4).
The solvent was removed under reduced pressure and resulting oil 71 (1.14 g, 35%) was
purified by medium pressure chromatography, CH2Cl2/petroleum ether (2:3). 1H NMR
(CDCl3): 2.27 (t, J = 7.5 Hz, 2H), 2.38 (q, J = 7.8 Hz, 2H), 4.06 (t, J = 7.8 Hz 1H), 7.1 7.3 (m, 10H).
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4,4-Diphenylbutyric acid (73).202 A solution of -phenyl--butyrolactone 72 (1.62 g,
10.0 mmol) in anhydrous benzene (50 mL) was added in small proportions to anhydrous
aluminum chloride (1.46 g, 11.0 mmol). The mixture was stirred at rt for 5 h, and then
quenched with 2 N HCl. The benzene layer was extracted with ether (3 × 25 mL).
Combined extracts were washed with water and dried (MgSO4) after filtration,
evaporation of the solvent afforded the compound 73 (2.0 g, 84%) as colorless crystals:
mp 88 - 90 °C. (lit202 mp 89 - 91 °C) 1H NMR (CDCl3): 2.3 (q, J = 7.8 Hz, 2H), 2.6 (t, J =
7.5 Hz, 2H), 4.1 (t, J = 7.8 Hz, 7.1 - 7.3 (m, 10H).
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C NMR (CDCl3): 25.1, 27.2, 50.2,

126.2, 128.3, 129.3, 143.0, 178.2.

N-Methyl-4,4-diphenylbutanamide (75). Thionyl chloride (1.18 g, 10.0 mmol) was
added under N2 to a stirred solution of compound 73 (0.5 g, 2.0 mmol) in anhydrous
benzene (4 mL). The solution was heated at reflux (2 h), allowed to cool and the excess
benzene and thionyl chloride were removed under reduce pressure to provide an oil. The
oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an ice bath (0 °C).
Methylamine/THF (2 M, 0.31 g, 10 mmol) solution was added dropwise into the stirred
solution, and the mixture was stirred at rt (2 h). The solvent was removed under reduced
pressure to give a white solid. Water (20 mL) was added, and the suspension was
extracted with EtOAc (3 × 25 mL). The combined extracts were washed with water, brine
and dried (MgSO4). Removal of solvent under reduced pressure gave the crude amide.
The

resulting

amide

was

purified

using

medium

pressure

chromatography,

CH2Cl2/Acetone (9:1) to yield 75 (0.42 g, 80%). 1H NMR (CDCl3): 2.1 (t, J = 7.5 Hz,
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2H), 2.38 (q, J = 7.8 Hz, 2H), 2.74 (d, J = 5.1Hz 3H), 3.9 (t, J = 7.8 Hz 1H), 7.1 - 7.3 (m,
10H).

N,N-Dimethyl-4,4-diphenylbutanamide (76)247. Thionyl chloride (1.18 g, 10.0 mmol)
was added under N2 to a stirred solution of compound 73 (0.5 g, 2.0 mmol) in anhydrous
benzene (4 mL). The solution was heated at reflux (2 h), allowed to cool and the excess
benzene and thionyl chloride were removed under reduce pressure to provide an oil. The
oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an ice bath (0 °C).
Dimethylmethylamine/THF (2 M, 0.45 g, 10.0 mmol) solution was added dropwise into
the stirred solution, and the mixture was stirred at rt (2 h). The solvent was removed
under reduced pressure to give a white solid. Water (20 mL) was added, and the
suspension was extracted with EtOAc (3 × 25 mL). The combined extracts were washed
with water, brine and dried (MgSO4). Removal of solvent under reduced pressure gave
crude amide as an oil. The resulting oil was purified using medium pressure
chromatography, CH2Cl2/Acetone (9:1) to yield 76 (0.43 g, 85%). 1H NMR (CDCl3):
2.24 (t, J = 7.5 Hz, 2H), 2.39 (q, J = 7.2 Hz, 2H), 2.82 (d, J = 5.7 Hz, 3H), 3.97 (t, J = 7.2
Hz, 1H), 7.1 - 7.3 (m, 10H).

9,10-Dihydro-N-phenethylanthracene-10-carboxamide (77). Thionyl chloride (2.6 g,
22.0 mmol) was added under N2 to a stirred solution of compound 43 (1g, 4.4 mmol) in
anhydrous benzene (10 mL). The solution was heated at reflux (2 h), allowed to cool and
the excess benzene and thionyl chloride were removed under reduce pressure to provide
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an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in an ice bath
(0 °C). Phenylethylamine (1.0 g, 8.8 mmol) was added dropwise into the stirred solution,
and the mixture was stirred at rt (2 h). The solvent was removed under reduced pressure
to give a white solid. Water (20 mL) was added, and the suspension was extracted with
EtOAc (3 × 25 mL). The combined extracts were washed with water, brine and dried
(MgSO4). Removal of solvent under reduced pressure gave a crude solid. The resulting
amide was purified using medium pressure chromatography, CH2Cl2/Acetone (9:1) to
yield 77 (1.05 g, 73%). mp 140 - 143 °C. 1H NMR (CDCl3): 2.63 (t, J = 7.2 Hz, 2H) 3.43
(q, J = 7.2 Hz, 2H), 3.85 (s, 2H), 4.82 (s, 1H), 6.9 - 7.4 (m, 13H). 13C NMR (CDCl3): 
35.62, 39.70, 41.74, 54.53, 126.10, 127.8, 128.6, 138.2, 143.4, 170.9.

9,10-Dihydro-N-(3-phenylpropyl)anthracene-10-carboxamide (78). Thionyl chloride
(2.6 g, 22.0 mmol) was added under N2 to a stirred solution of compound 43 (1 g, 4.4
mmol) in anhydrous benzene (10 mL). The solution was heated at reflux (2 h), allowed to
cool and the excess benzene and thionyl chloride were removed under reduced pressure
to provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in
an ice bath (0 °C). Phenylpropylamine (1.0 g, 8.8 mmol) was added dropwise into the
stirred solution, and the mixture was stirred at rt (2 h). The solvent was removed under
reduced pressure to give a white solid. Water (20 mL) was added, and the suspension was
extracted with EtOAc (3 × 25 mL). The combined extracts were washed with water, brine
and dried (MgSO4). Removal of solvent under reduced pressure gave a crude solid. The
resulting amide was purified using medium pressure chromatography, CH2Cl2/Acetone
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(9:1) to yield 78 (1.15 g, 75%). 1H NMR (CDCl3): 1.63 (m, 2H), 2.46 (t, J = 7.2Hz, 2H),
3.15 (q, J = 7.2 Hz, 2H), 3.96 (d, J = 18.6 Hz, 1H), 4.16 (d, J = 18.6 Hz, 1H), 4.82 (s,
1H), 6.9 - 7.4 (m, 13H). 13CNMR (CDCl3):  29.2, 33.2, 40.20, 41.7, 54.2, 126.1, 126.8,
128.1, 128.7, 128.9, 138.0, 138.2, 143.4, 170.9.

9,10-Dihydro-N-(4-phenylbutyl)anthracene-10-carboxamide (79). Thionyl chloride
(2.6 g, 22.0 mmol) was added under N2 to a stirred solution of compound 43 (1 g, 4.4
mmol) in anhydrous benzene (10 mL). The solution was heated at reflux (2 h), allowed to
cool and the excess benzene and thionyl chloride were removed under reduced pressure
to provide an oil. The oil obtained was dissolved in anhydrous THF (4 mL) and cooled in
an ice bath (0 °C). Phenylbutylamine (1.0 g, 8.8 mmol) was added dropwise into the
stirred solution, and the mixture was stirred at rt (2 h). The solvent was removed under
reduced pressure to give a white solid. Water (20 mL) was added, and the suspension was
extracted with EtOAc (3 × 25 mL). The combined extracts were washed with water, brine
and dried (MgSO4). Removal of solvent under reduced pressure gave a crude solid. The
resulting amide was purified using medium pressure chromatography, CH2Cl2/Acetone,
(9:1) to yield 79 (1.13 g, 72%). 1H NMR (CDCl3): 1.48 (m, 4H), 2.5 (t, J = 7.2 Hz, 2H),
2.7 (t, J = 6.9 Hz, 2H), 3.91 (d, J = 18.3 Hz, 1H), 4.12 (d, J = 18.3 Hz, 1H), 7.0 - 8.4 (m,
13H).
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C NMR (CDCl3):  28.2, 29.2, 35.7, 40.60, 41.7, 54.2, 126.1, 126.8, 128.1,

128.7, 128.6, 138.0, 138.2, 143.4, 170.9.
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2-(Bromomethyl)benzaldehyde (81).212 A solution of 2-(bromomethyl)benzonitrile 80
(5.0 g, 25.5 mmol) in dried CH2Cl2 (75 ml) was cooled in an ice-water bath and
maintained under an inert atmosphere. A 1.0 M solution of diisobutyl aluminum hydride
(26.0 mL, 26.0 mmol) in heptane was added in a dropwise manner over a period of 30
min. The resulting solution was then allowed to warm slowly to rt with stirring in a
period of 3 h by removing the ice-water bath. The reaction mixture was cooled again with
an ice-bath, and then directly poured into a 1000 mL beaker containing ice (100 g) and a
precooled HBr aqueous solution (6.0 N, 100 mL). The resulting mixture was vigorously
stirred for 1 h and then extracted with CH2Cl2. The combined extracts were washed with
1 N NaHCO3, water, and dried (MgSO4). Evaporation of solvent gave product 81 (4.9 g,
97% yield) as a clear brown liquid. 1H NMR (CDCl3): 4.91 (s, 2H), 7.45 (d, J = 5.4 Hz
1H ), 7.52 (d, J = 5.7 Hz, 1H), 7.56 (d, J = 5.4 Hz, 1H), 7.83 (d, J = 5.7 Hz, 1H), 10.23
(s, 1H).

2-((Naphthalen-2-yl)methyl)benzaldehyde (82). 2-naphthylboronic acid (1.5 g, 8.7
mmol) was added to a well stirred solution of 81 (1.0 g, 5.0 mmol) with potassium
phosphate (21.2 g, 10.0 mmol) and palladium tetrakistriphenyl (5mol % 0.288 g) in dry
THF (20 ml). The reaction mixture was stirred for a while at rt and heated to reflux for 8
h. The reaction mixture was cooled to rt, filtered and washed with CH2Cl2 (50 ml). The
filtrate was evaporated to obtain a brown oily liquid as product 82 which was further
purified by medium pressure column chromatography, petroleum ether/EtOAc (9:1) to
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give semi-solid 82 (0.85 g, 62%). 1H NMR (CDCl3): 4.0 (s, 2H), 7.1 - 7.8 (m, 10H), 10.3
(s,1H).

2-((6-Methoxynaphthalen-2-yl)methyl)benzaldehyde (83).
6-methoxy-2-napthylboronic acid (1.5 g, 7.5 mmol) was added to a well stirred solution
of 81 (1.0 g, 5.0 mmol) with potassium phosphate (21.2 g, 10.0 mmol) and palladium
tetrakistriphenyl (5mol % 0.288 g) in dry THF (20 ml). The reaction mixture was stirred
for a 15 min at rt and heated to reflux for 8 h. The reaction mixture was cooled to rt,
filtered and washed with CH2Cl2 (50 ml). The filtrate was evaporated to obtain a brown
oily liquid as product 63 which was further purified by medium pressure column
chromatography, petroleum ether/EtOAc (9:1) to give a pale yellow solid (0.9 g, 65%).
mp 67 - 70 °C. 1H NMR (CDCl3): 3.9 (s, 3H), 4,58 (s, 2H), 7.1 - 7.9 (m, 10H), 10.3
(s,1H).

2-Amino-1-(2-((naphthalen-2-yl)methyl)phenyl)ethanol (84). Trimethylsilylcyanide
(1.05 g, 10.6 mmol) was added dropwise to a well stirred solution of 82 (1.75 g, 7.1
mmol) and ZnI (0.054 g, 0.28 mmol) cooled in an ice bath. The reaction mixture was
allowed to warm to rt and then heated to 60 °C for 30 min. The reaction mixture was
cooled back to 0 °C and lithium aluminum hydride (0.96 g, 25.32 mmol) was added in a
dropwise manner. The reaction mixture was further refluxed for 12 h, cooled to rt, and
1ml water and 1ml NaOH were added. The reaction mixture was then diluted with
CH2Cl2 (50 ml) and filtered through celite. The filtrate evaporated under reduced pressure
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to obtain a red oily liquid which was further purified by medium pressure column
chromatography, CH2Cl2/MeOH (9:1) to get 84 (0.8 g, 45%). 1H NMR (CDCl3): 1.8 (bs,
2H), 2.64 (m, 2H), 4.1 (s, 2H), 4.7 (m, 1H), 7.0 - 7.8 (m, 10H).

2-Amino-1-(2-((6-methoxynaphthalen-6-yl)methyl)phenyl)ethanol (85).
Trimethylsilylcyanide (0.94 g, 9.49 mmol) was added dropwise to a well stirred solution
of 83 (1.75 g, 6.33 mmol) and ZnI (0.048 g, 0.253 mmol) cooled in an ice bath. The
reaction mixture was allowed to warm to rt and than heated to 60 °C for 30 min. The
reaction mixture was cooled back to 0 °C and lithium aluminium hydride (0.96 g, 25.32
mmol) was added in a dropwise manner. The reaction mixture was further refluxed for 12
h, cooled to rt, and 1 ml water and 1ml NaOH were added. The reaction mixture was then
diluted with CH2Cl2 (50 ml) and filtered using celite. The filtrate evaporated under
reduced pressure to obtain red oily liquid which was further purified by medium pressure
column chromatography, CH2Cl2/MeOH (9:1) to get 85 (0.75 g, 40%). mp 150 - 153 °C.
1

H NMR (CDCl3): 1.75 (bs, 2H), 2.64 (m, 2H), 3.9 (s, 3H), 4.16 (s, 2H), 4.82 (m, 1H),

7.0 - 7.66 (m, 10H).

Methyl 4-benzoylbenzoate (87). To a solution of 4-benzoylbenzoic acid 86 (0.5 g, 2.2
mmol) in methanol (10 mL) was added 0.5 ml of concentrated H2SO4 and refluxed for 4
h. The reaction mixture was cooled to rt and solvent was evaporated under vacuum.
Water was added to the residue which was extracted with EtOAc (3 × 20 mL). The
combined EtOAc extracts were washed with water, brine, and dried (MgSO4). The
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solvent was evaporated under reduced pressure to give a yellow oil 87 (0.5 g, 95%). 1H
NMR(CDCl3): 3.97 (s, 3H), 7.23 - 7.81 (m, 9H); 13C NMR(CDCl3):  51.8, 60.2, 128.2,
129.2, 130.2, 132.5, 165.8.

(E,Z)-Methyl 4-(4-(dimethylamino)-1-phenylbut-1-enyl)benzoate (88).
3-Dimethylaminopropyl triphenylphosphonium bromide (0.847 g, 1.9 mmol) was
dissolved in 10 ml of THF and 1.6M n-butyllithium (0.133 g, 2.09 mmol) was added
dropwise under cooling in a dry ice-acetone bath at -78 °C. The mixture was then stirred
for 30 min under ice cooling. A solution of compound 87 (0.475 g, 1.9 mmol) in 10 ml
THF was added to the mixture and stirring was continued for 30 min. The reaction
mixture was brought to rt and was stirred for another 1h. Brine was added to the reaction
mixture and extracted with EtOAc (3 × 20 mL). Extract was washed with water, brine
and dried (MgSO4). The solvent was evaporated under reduced pressure to give pale
brown oily substance 88 as a mixture of geometrical isomers (E/Z = 1/2) which was
further purified by medium pressure column chromatography, CH2Cl2/MeOH (9:1) to
obtain 88 (0.53 g 90%). 1H NMR(CDCl3): 2.3 (q, J = 7.8 Hz, 2H), 2.20 (s, 6H), 2.44 (t, J
= 6.8 Hz, 2H), 3.92 (s, 3H), 6.19 (t, J = 7.8 Hz, 1H), 6.22 (t, J = 7.8 Hz, 1H), 7.17 7.8.0 (m, 9H); 13C NMR(CDCl3):  25.06, 44.11, 51.8, 60.2, 126.4, 128.6, 129.2, 165.4.

(E,Z)-4-(4-(Dimethylamino)-1-phenylbut-1-enyl)benzoic acid (89).249 Compound 88
(0.5 g, 1.6 mmol) was dissolved in methanol (5 mL), 1 N NaOH (3 mL) was added and
resulting mixture was stirred overnight at rt. 1 N HCl was added to the reaction mixture
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and concentrated to dryness. After a CHCl3:MeOH (5:1) mixture (10 mL) was added to
the residue, the resulting mixture was stirred for 30 min and filtered with celite. The
filtrate was concentrated and purified by column chromatography to obtain a yellow
gummy solid. The solid obtained was triturated with ether to yield precipitate of 89 (0.42
g, 89%) which was collected by filtration. 1H NMR (CD3OD): 1.86 (m, 2H), 2.13 (s, 6H),
2.52 (m, 2H), 6.19 (t, J = 7.2 Hz 1H), 6.24 (t, J = 7.2 Hz 1H), 7.17 - 7.8.0 (m, 9H); 13C
NMR(CD3OD):  25.07, 48.11, 60.8, 115.3, 126.4, 128.6, 130.2, 169.4.

Ethyl 2-(bromomethyl)benzoate (91).237 A mixture of ethyl 2-methylbenzoate 90 (1.0 g,
6.0 mmol), N-bromosuccinimide (1.12 g, 6.3 mmol) and benzoyl peroxide (0.145 g, 0.6
mmol) in 40 mL carbon tetrachloride was heated under reflux for 4 h. The reaction
mixture was then cooled to rt with additional cooling using an ice bath for 1 h. The
succinimide was separated by filtration and the filtrate was evaporated under vacuum to
give 91. The crude product (purity > 95%) obtained was in quantitative yield and was
used as such in next step. 1H NMR(CDCl3): 1.45 (t, J = 7.5 Hz, 3H), 4.40 (q, J = 7.5 Hz,
2H), 4.98 (s, 2H), (7.2 - 8.2 (m, 4H); 13C NMR(CDCl3):  15.1, 30.9, 62.9, 129.2, 129.6,
130.3, 130.6, 133.8, 139.6, 170.2.

2-(3-Carboxybenzyloxy)phenylacetic

acid

(93).237

A

mixture of ethyl

2-(4-

hydroxyphenyl) acetate (0.73 g, 4.1 mmol), compound 91 (1.0 g, 4.1 mmol), potassium
carbonate (2.26 g, 16.4 mmol) and potassium iodide (0.068 g, 0.41 mmol) in 50 mL of
butanone was refluxed for 16 h, cooled, and filtered and the filtrate concentrated to one
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third its original volume. Water was added to the mixture which was extracted with ether
(3 × 25 mL). The ether extract was washed with 5% NaOH and water, dried (MgSO4),
filtered and concentrated in vacuum to give an oil (92) which was refluxed with
potassium hydroxide (3.67 g, 65.6 mmol) in 40 mL of ethanol for 12 h. The mixture was
concentrated and the residue was dissolved in water and extracted with ether.
Acidification of the aqueous layer provided a yellow solid which was purified by medium
pressure column chromatography, Petroleum ether/EtOAc (9:1) to obtain product 93
(0.49 g, 58%). mp 176 - 178 °C. (lit237 176 – 178 °C). 1H NMR(CDCl3): 3.51 (s, 2H),
5.44 (s, 2H), 6.9 - 8.0 (m, 8H);
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C NMR(CDCl3):  39.8, 68.1, 114.6, 126.1, 126.1,

127.2, 127.4, 128.8, 130.2, 130.7, 132.2, 139.5, 158.0, 169.1, 174.8.

11-Methylene-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid methyl ester (94).236 To a
suspension of methyltriphenylphosphonium bromide (0.6 g, 1.68 mmol) in anhydrous
THF (2 mL) was added 2.5 N n-BuLi (0.023 g, 0.37 mmol) solution in hexane under N2
atmosphere at 0 °C, and the mixture was stirred under same conditions for 1 h. A solution
of compound 31 (0.1 g, 0.37 mmol) in THF (2 mL) was added and the resulting mixture
was stirred at rt for 2 h. After being concentrated, the reaction mixture was diluted with
water, washed with ether and then neutralized (10% HCl). The solution was concentrated
and the residue was dissolved in MeOH (10 mL) containing p-TsOH·H2O (0.091 g, 0.48
mmol) and refluxed for 2 h. After being concentrated, the reaction mixture was diluted
with EtOAc, washed with water and dried (MgSO4). The solvent was evaporated in
vacuum to obtain 94 which was purified by medium pressure column chromatography,
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hexane/EtOAc (2:1) to obtain 94 as an oil (0.045 g, 45%). 1H NMR(CDCl3): 3.60 (s, 2H),
3.73 (s, 3H), 5.19 (s, 2H), 5.32 (s, 1H), 5.74 (s, 1H), 6.82 (d, J = 8.4 Hz, 1H), 7.11 (d, J =
8.4Hz, 1H), 7.31 - 7.39 (m, 5H);

13

C NMR(CDCl3):  39.85, 51.64, 70.39, 117.09,

119.52, 125.10, 126.14, 126.46, 127.09, 127.68, 128.70, 130.04, 130.48, 133.74, 143.38,
147.61, 154.70, 171.79.

2-[(4-(2-Hydroxyethyl)phenoxy)methyl]benzoic acid (96). A mixture of 4-(2hydroxyethyl)phenol (3.12 g, 22.62 mmol), ethyl α-bromo-o-toluate 91 (5.0 g, 20.56
mmol), potassium carbonate (8.52 g, 61.68 mmol) and potassium iodide (0.34 g, 2.056
mmol) in 75 mL of butanone was refluxed for 16 h, cooled and then filtered. The filtrate
was concentrated to one third its original volume. Water (50 mL) was added to the
mixture and extracted with ether (3 × 25 mL). Ether extracts were washed with 5%
NaOH, water and dried (MgSO4). The ether layer was concentrated in vacuum to obtain
the intermediate compound 95 which was refluxed with sodium hydroxide (0.79 g, 19.97
mmol) in 30 ml of methanol for 12 h. The resulting mixture was concentrated and the
residue obtained was dissolved in water and extracted with ether (3 × 25 mL).
Acidification of aqueous layer provided 96 as an oil (2.0 g, 57%). 1H NMR(CDCl3): 2.76
(t, J = 7.2 Hz, 2H), 3.72 (t, 7.2 Hz 2H), 5.4 (s, 2H), 6.89 - 8.05 (m, 8H);
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C

NMR(CDCl3):  37.43, 62.50, 67.33, 113.83, 126.39, 126.62, 127.97, 129.02, 130.01,
130.68, 131.44, 138.99, 156.71, 168.34.
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2-((4-(2-Acetoxyethyl)phenoxy)methyl)benzoic acid (97). Anhydrous acetyl chloride
(0.034 g, 0.44 mmol) was added dropwise to a solution of compound 96 (0.1 g, 0.367
mmol) in anhydrous THF (4 mL). The reaction mixture was stirred at rt overnight. THF
was evaporated and the residue obtained was washed with water and extracted with
CH2Cl2 to obtain the acetylated product 97 (0.109 g, 95%). 1H NMR(CDCl3): 2.09 (s,
3H), 2.92 (t, J = 7.8 Hz, 2H), 4.29 (t, J = 7.8 Hz, 2H), 5.58 (s, 2H), 6.97 - 8.23 (m, 8H);
C NMR(CDCl3):  20.57, 33.81, 64.85, 67.82, 114.52, 114.63, 114.70, 126.10, 126.87,
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126.91, 129.50, 129.79, 131.27, 133.14, 140.37, 157.01, 170.02, 171.75.

2-(6,11-Dihydro-11-oxo-dibenz[b,e]oxepin-2-yl)ethanol (98).239 Compound 97 (0.2 g,
0.63 mmol) was dissolved in CH2Cl2 (4 mL) and trifluroacetic anhydride (0.2 g, 0.95
mmol) was added followed by a catalytic amount of borontrifluoride etherate. The
reaction mixture was heated to 40 °C for 4 h and then washed with sat NaHCO3 and
water. The organic phase was dried (MgSO4), filtered and concentrated in vacuum to oil.
The crude product obtained was subjected to hydrolysis under basic conditions to get an
oil that was purified by medium pressure column chromatography, CH2Cl2/CH3OH (9:1)
to obtain 98 as an oil (0.145 g, 90%). 1H NMR(CDCl3): 2.90 (t, J = 6.6 Hz 2H), 3.89 (t, J
= 6.6 Hz, 2H), 5.18 (s, 2H), 7.0 - 8.1 (m, 7H); 13C NMR(CDCl3):  37.68, 63.02, 73.16,
120.44, 124.71, 127.36, 128.80, 129.01, 131.29, 131.94, 132.34, 135.19, 135.94, 140.0,
159.58, 190.77.
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6,11-Dihydro-11-oxo-dibenz[b,e]oxepin-2-ethyloxy(tert-butyl)dimethylsilane (99). To
a solution of compound 98 (0.1 g, 0.398 mmol) in DMF (4 mL) at 0 °C under N2, tertbutyldimethylsilyl chloride (0.065 g, 0.437 mmol) and imidazole (0.040 g, 0.597 mmol)
was added. The reaction mixture was then allowed to warm to rt and stirred overnight.
Resulting mixture was diluted with an equal volume of chloroform, washed with water
and brine. The organic layer was dried (MgSO4), filtered and concentrated in vacuum to
give the product 99. The product obtained was purified by medium pressure column
chromatography, 3%CH3OH/CH2Cl2 to yield compound 99 as an oil (0.13 g, 90%). 1H
NMR(CDCl3): 0.04 (s, 6H), 0.92 (s, 9H), 2.88 (t, J = 6.6 Hz, 2H), 3.85 (t, J = 6.6 Hz,
2H), 5.2 (s, 2H), 7.0 - 8.1(m, 7H); 13C NMR(CDCl3):  -5.76, 17.91, 25.52, 38.07, 63.82,
73.20, 119.99, 124.57, 127.32, 128.77, 129.0, 131.44, 132.22, 132.66, 135.25, 136.23,
140.16, 159.45, 190.73.

(E,Z)-11-[4-Methylpentylidene]-6,11-dihydrobenz[b,e]oxepin-2-ethyloxy(tertbutyl)dimethylsilane

(100).

To

a

suspension

of

4-(methylpentane)

triphenylphosphonium bromide (0.927 g, 2.17 mmol) in anhydrous THF (5 mL) was
added lithium bis(trimethylsilyl)amide (0.726 g, 4.34 mmol) in a dropwise manner. The
resulting orange colored solution was stirred for 30 min at 0 °C and slowly brought to rt
and stirring was continued for 1 h. To the deep orange colored solution was then added
the compound 99 (0.4 g, 1.085 mmol) dissolved in THF (3 mL) and the reaction mixture
was stirred for 12 h at rt. The reaction was then quenched by adding NH4Cl solution to
the mixture. The THF was evaporated and residue was extracted with ethyl acetate (3 ×
136

25 mL). The solvent was dried (MgSO4), filtered and concentrated in vacuum to yield an
oil. This was purified by medium pressure column chromatography, CH2Cl2/Petroleum
ether (7:3) to give compound 100 as a mixture of geometrical isomers (E/Z = 3/7) as an
oil (0.25 g, 53%). 1H NMR(CDCl3): 0.06 (s, 6H), 0.93 (s, 9H), 1.44 (d, J = 7.8 Hz, 6H),
1.65 (m, 1H), 2.23 (q, J = 8.1 Hz, 2H), 2.48 (q, J = 8.1 Hz, 2H), 2.80 (t, J = 6.9 Hz, 2H),
3.83 (t, J = 6.9 Hz, 2H), 5.2 (s, 2H), 5.72 (t, J = 7.5 Hz, 0.7H), 6.06 (t, J = 7.5 Hz, 0.3H),
6.8 - 7.4 (m, 7H);
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C NMR(CDCl3):  -5.71, 17.99, 22.14, 25.59, 27.18, 27.32, 38.33,

38.69, 64.42, 70.01, 118.87, 123.54, 125.87, 127.11, 127.62, 128.30, 129.31, 131.45,
133.4, 136.83, 138.34, 145.45, 153.43.

(E,Z)-(11-[4-Methylpentylidene]-6,11-dihydrobenz[b,e]oxepin-2-ethyl alcohol (101).
To a solution of Compound 100 (0.170 g, 0.389 mmol) in anhydrous THF (4 mL), tertbutyl ammonium fluoride (0.203 g, 0.778 mmol) was added in a dropwise manner at 0 °C
under N2. The resultant mixture was stirred for 1 h then allowed to warm to rt and stirring
was continued for another 1 h. The reaction mixture was then concentrated in vacuum
and the residue obtained was washed with water and extracted with EtOAc (3 × 25 mL) It
was purified by medium pressure column chromatography, hexane/EtOAc (1:1) to yield
product 101 as an oil (0.119 g, 95%). 1H NMR(CDCl3): 0.92 (d, J = 6.6 Hz, 6H), 1.44 (q,
J = 7.8 Hz, 2H), 2.21 (m, J = 7.5 Hz, 1H), 2.45 (q, J = 7.5 Hz, 2H), 2.81 (t, J = 6.3 Hz
2H), 3.84 (q, J = 6.3 Hz, 2H), 5.2 (bs, 2H), 5.7 (t, J = 7.8 Hz, 0.7H), 6.04 (t, J = 7.8 Hz,
0.3H), 6.7 - 7.3 (m, 7H);
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C NMR(CDCl3):  22.10, 26.75, 27.30, 37.84, 38.43, 63.41,

69.98, 118.27, 123.76, 125.85, 127.01, 127.59, 127.97, 128.61, 129.12, 129.49, 131.43,
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133.16, 138.12, 145.38, 153.66. Anal Calcd for (C22H26O2·0.25 H2O) C, 80.82; H, 8.16
Found: C, 80.49, H, 8.48. ESIMS (+ ve) calcd for C22H26O2 [(M+H)+] 323.19, found
323.26

7.2 Molecular Modeling
Molecular modeling investigations were conducted using the SYBYL 7.1
molecular modeling package (Tripos International, St. Louis, MO) on MIPS R14K- and
R16K-based IRIX 6.5 Silicon Graphics Fuel and Tezro workstations. Molecular
mechanics-based energy minimizations were performed using the Tripos Force Field with
Gasteiger-Hückel charges, a distance-dependent dielectric constant  = 4 D/Å and a nonbonded interaction cutoff = 8 Å and were terminated at an energy gradient of 0.05
kcal/(mol×Å). The H1 (P35367) and 5-HT2A (P28233) receptor sequences were retrieved
from the ExPASy Proteomics Server (http://www.expasy.org/) and aligned with a profile
of several related class A GPCRs (human, dopamine D3 (P35462), muscarinic cholinergic
M1 (P11229), vasopressin V1a (P37288), adrenergic 2 (P07550), -opioid (P41143), 5HT2A (P28223), dopamine D2 (P14416), bovine rhodopsin (P02699) using the ClustalX159
program. Within ClustalX, the slow-accurate alignment algorithm was used, the
BLOSUM matrix series was employed and the gap opening penalty was increased from
10.0 to 15.0 to help maintain the continuity of the transmembrane helical segments. The
alignment was carried out in two separate steps as reported by Bissantz, et al.250 Manual
adjustment of the ClustalX alignment was required to properly align the disulfideforming cysteine residues in the e2 loop. The result was an unambiguous alignment in the
138

transmembrane (TM) helical regions of both the H1 and 5-HT2A sequences with that of the
2–adrenoceptor. This alignment, along with a file containing the atomic coordinates of
the adrenergic 2 receptor (PDB ID = 2RH1), was used as input to the MODELLER162
software package to generate a population of 100 different H1 or 5-HT2A homology
models. Each of these receptors was subsequently energy-minimized. An analogous
method was used in the case of homology models generated from bovine rhodopsin as the
template. In this case, atomic coordinates of the bovine rhodopsin receptor (PDB ID =
1U19), were used as input to the MODELLER software package.
The

automated

docking

program

GOLD

version

3.01

(Cambridge

Crystallographic Data Centre, Cambridge, UK) was then used to dock diphenhydramine,
AMDA (1) and the high-affinity matrix compounds 9 and 18 into each of the 100
receptor models. In the case of modeling investigations for the carboxylate- substituted
compounds, olopatadine and acrivastine were added to the above set of compounds.
Based on the fitness function values, steric and electronic interactions of the docked
poses and reported site-directed mutagenesis data, one receptor model was selected to
represent the ligand binding site of the H1 and 5-HT2A receptors. These models were
subsequently analyzed using PROCHECK161 and the ProTable facility with in SYBYL to
assess the geometric integrity of various structural elements (bond lengths, torsion angles,
etc.) within each receptor. After checks for stereochemical integrity, the receptor models
were used for the docking of all the target compounds. Ligand molecules were sketched
using SYBYL and energy-minimized using the same parameters as were used for the
receptor models. Basic amines were protonated to form ammonium ions. GOLD was
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used to dock each ligand structure (using the parameter set defined by the “standard
default settings” option) into the final receptor model. Each receptor-ligand complex was
then energy-minimized with its best-ranked docking pose.
The HINT scoring function (version 3.11S β) was utilized to explore and visualize
hydropathic interactions by analyzing the ligand-receptor complexes generated by the
automated docking program GOLD. The interaction scores were calculated for the
energy-minimized highest-ranked ligand conformation. The receptors (5-HT2A and H1)
and ligands were partitioned using the “dictionary” and “calculated” methods
respectively. The „All‟ hydrogen treatment option was employed in the H-bonding
model, and hydrogen atoms at unsaturated positions as well as alpha to a heteroatom
were considered to participate in H-bonding interactions. The inferred solvent model,
which considers the partition of each residue based on its hydrogen count, was selected.
The „+20 -NH- SASA‟ chain H-bond correction option was selected. Intermolecular
HINT Tables were calculated for all (hydrophobic and polar) interactions with an
interaction output cutoff value of 1.0. Finally, hydrophobic and polar interaction HINT
maps were generated separately for a region extending 8 Å beyond the docked ligands.
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